Molecular determinants of Influenza A virus cross-species jumps

￼ by Coburn, Alice Miranda
  
 
 
 
 
 
Coburn, Alice Miranda (2017) Molecular determinants of Influenza A 
virus cross-species jumps PhD thesis. 
 
 
 
 
http://theses.gla.ac.uk/8394/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
Molecular determinants of Influenza 
A virus cross-species jumps 
 
 
Alice Miranda Coburn, MA 
 
Submitted in partial fulfillment of the requirements for the Degree of Doctor of 
Philosophy in Molecular Virology 
 
MRC-University of Glasgow Centre for Virus Research 
 Institute of Infection, Immunity and Inflammation  
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
 
May 2017  
 Page ii 
 
Abstract 
 
Influenza A viruses (IAVs) represent a significant risk to human and animal health 
and thus determining the mechanisms of cross-species transmission is critical in 
understanding viral emergence. H3N8 equine influenza virus (EIV) is a virus of avian 
origin that emerged in horses in the early 1960s and is still circulating in horses despite the 
availability of vaccines. Therefore, H3N8 EIV provides unique opportunities to study the 
underpinning mechanisms of cross-species jumps and adaptation in mammalian hosts. 
 
The aim of this project was to determine the role of evolution on EIV adaptation to 
the horse. To this end, equine and avian cell lines were infected as well as horse tracheal 
explants with a panel of phylogenetically distinct EIVs and compared their infection 
phenotypes. Viral replication was quantified and changes in the histology and ciliary 
activity of infected explants were assessed to compare the phenotype of infection of each 
virus. Phylogenetically distinct EIVs exhibited different infection phenotypes: while early 
EIVs grew more efficiently in avian cells, late EIVs grew to higher titres in equine 
explants. This phenotype was demonstrated to be largely due to the late EIV viral 
polymerase. Using an in vitro measure of polymerase activity, late EIVs were observed to 
have more efficient activity in mammalian cells than early EIVs. The Polymerase Acidic 
(PA) and Nucleoprotein (NP) segments were shown to be the greatest drivers of the 
mammalian-adapted polymerase phenotype. Including either of these segments from a late 
EIV in the polymerase complex significantly increased minireplicon activity. Our results 
suggest that EIV adapted to the horse along its evolutionary history partly by mutations in 
the PA and NP genes.  
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1 Introduction  
 
1.1 Influenza Relevance 
 
Influenza A viruses (IAVs) are significant pathogens of many species of birds and 
mammals, including humans, which can cause debilitating illness and death. Canonically, 
the natural reservoir of IAVs is wild water birds from which strains can undergo host 
species jump events, and establish new lineages in other species. These lineages can adapt 
to their new hosts to give rise to species-specific strains, in a process that may or may not 
require particular host adaptive mutations. Adaptation in the novel host may increase viral 
attachment to cells, cell entry, viral replication within the host cell, or act to aid the virus 
evade the host immune response. Crucially, to establish in a new species, the virus must be 
able to transmit efficiently between individuals.  
 
1.2 The History of Influenza 
 
In 412 BC Herodotus records that he suffered with a respiratory congestion, 
believed to be the first record of an influenza virus1. Millennia later, influenza still affects a 
huge proportion of the world each year. Up to 20% of the population of the United States2 
is estimated to experience seasonal influenza infections each year1, and this number rises in 
vulnerable people such as the elderly. The seasonal influenza burden is estimated to have 
cost the US economy 87 billion dollars in medical bills and lost productivity in 20033, as 
well as led to over seven thousand deaths2. Outbreaks of new strains of influenza have the 
potential to sweep through a naïve population, with devastating effect. The 1918 outbreak 
of Spanish Influenza is estimated to have infected a quarter of the global population, and 
led to the deaths of 50 million people4. Influenza A viruses in animals also pose an 
economic burden, with chicken culls estimated to cost the Asian market 3.3 billion dollars 
in 20165. Mexican swine flu had such an impact on the farmers of the region that swine 
production has not yet recovered to pre-2009 levels6.  
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1.3 Influenza Virology 
1.3.1 Genomic Organisation 
 
IAVs belong to the Orthomyxoviridae. The genome is comprised of eight segments 
of single stranded negative-sense ribonucleic acid (RNA). Each genomic segment encodes 
one or more proteins. Multiple proteins are known to be expressed from segments 7 and 8 
by differential splicing, and from segments 2 and 3 using alternate open reading frames  
(ORFs). A summary of currently known gene products of IAVs is shown in Table 1.1, 
although expression of some minor proteins is strain-specific7,8. 
 
Segment Protein name Function 
1 Polymerase Basic 2 
(PB2) 
Internal protein, virus replication. Cap snatching. 
2 
 
Polymerase Basic 
(PB1) 
Internal protein, virus replication. Strand 
elongation 
PB1 – F2 9 Mitochondrial targeting and apoptosis 
PB1- N40  
3 Polymerase Acidic 
(PA) 
Internal protein, virus replication 
PA-X 7 Endonuclease, cap-snatching 
PA-N155 8 Undefined 
PA-N182 8 Undefined 
4 Haemagglutinin (HA) Surface glycoprotein, viral attachment, antigenic 
determinant.  
5 Nucleoprotein (NP) RNA coating, nuclear targeting 
6 Neuraminidase (NA) Surface glycoprotein, antigenic determinant, virus 
release from host cells 
7 Matrix 1 (M1) Membrane protein stability 
Matrix 2 (M2) Membrane protein, ion channel, viral uncoating 
8 Non-structural 1 
(NS1) 
Internal protein, interferon antagonist 
Nuclear export 
protein (NEP) 
Internal protein, nuclear export protein (NEP). 
Previously known as NS2 
 
Table 1.1: Summary of influenza proteins. Adapted from Jagger et al 20127 
 
1.3.2 Influenza Virus Taxonomy  
 
Influenza viruses belong to the Orthomyxoviridae family, and comprise Influenza 
A, B and C viruses (IAV, IBV and ICV respectively). Recently, the Influenza D Virus, 
which is very distinct with only 50% nucleotide identity to its closest relative ICV, has 
been confirmed within this family10.  Figure 1.1 is a phylogenetic tree illustrating the 
family. 
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Figure 1.1: Phylogenetic tree of the Orthomyxoviridae based on the Maximum-Likelihood model. Figure 
adapted from Carnell et al 201511.  
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The earliest divergence of the Orthomyxoviridae clade was when ICV and IDV 
split off from the others ancestrally as demonstrated by these having only seven segments, 
while IAV and IBVs have eight. The IAV and IBV linages diverged at least several 
hundred years ago12. IBV and ICV have been isolated almost exclusively from humans, so 
it is interesting to note that IAV has a significantly extended host range in comparison. 
IAV has established defined linages in multiple species, including waterfowl, domestic 
poultry, swine, horses, dogs and humans. For this reason each influenza virus isolate is 
defined first by the genus, then by the species from which it was isolated, the location and 
the year of isolation. The convention is to include only the final two digits of years before 
2000, but all four digits of subsequent years. If more than one isolate was recovered from 
the same in the same location and year, an isolate number is inserted between the location 
and year. For instance, the third IAV isolated from a horse in Mongolia in 2013 is named 
A/equine/Mongolia/3/2013. IAVs are also subtyped by their external proteins, reflecting 
which of the 19 HA and 11 NA protein variants are expressed on the lipid envelope. Thus, 
the equine virus mentioned above belongs to the H3N8 subtype.  
  
1.3.3 Virus Structure 
The IAV virion is highly pleomorphic, exhibiting both spherical and filamentous 
particles in nature with an average diameter of 100nm1,13 although the filamentous particles 
can be much longer. The structure of a spherical IAV virion is schematically represented in 
Figure 1.2 to illustrate the components. The virus genome is divided into 8 segments of 
unequal sizes. Each segment is complexed into ribonucleoprotein (RNP) units. The RNP 
consists of a viral genome segment wrapped by the nucleoprotein (NP) and held in a stem-
loop shape by complementary untranslated regions (UTRs) forming a “pan handle” shape. 
This forms the viral promoter, which also binds the heterotrimeric viral polymerase, made 
up of the two polymerase basic proteins (PB1 and PB2) and the polymerase acidic protein 
(PA). These eight structures are enclosed by the capsid of matrix protein M1 and the 
external lipid envelope, which contains the viral haemagglutinin (HA) and neuraminidase 
(NA) proteins, and the ion channel M2. IAVs also encode non-structural proteins, such as 
NS1 and NEP, which act to facilitate viral replication by evading host restriction points 
e.g. RNP transport 14. 
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Figure 1.2. Schematic representation of Influenza A virion. HA (purple), NA (orange) M2 (black), envelope 
dashed line, M1 matrix solid line. NP light blue, RNA dark blue. PB1 red, PB2 olive, PB1 teal.  
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The IAV has a complex multi-stage life cycle, which requires the co-option of host 
machinery at every stage as it is an obligate intracellular parasite. Once the virus has bound 
to and entered a suitable host cell, the RNP units are released into the cytoplasm. As IAV 
replicates in the cell nucleus, the viral segments must be trafficked to the nucleus for 
transcription and replication to occur. New virion components must be assembled into 
functional viruses before they bud out of the plasma membrane and repeat the process. The 
virus has evolved to exploit the host machinery to produce its protein and RNA 
components, as well as to avoid restriction and/or detection by cellular defences. A 
schematic of the viral replication cycle is displayed in Figure 1.3.  
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Figure 1.3: Replication cycle of the IAV. Figure adapted from Mehle et al 200915. 
 
  
 Page 8 
 
 
1.3.4 Replication cycle  
 
The HA protein is used in attachment to the viral receptor, sialic acid (SA), a 
monosaccharide component of cell surface glycoproteins. HA is the main surface protein 
of the virus, and as such is the major target for antibody generation in the host immune 
response. For this reason, HA shows high variation between strains to reduce antibody 
cross reactivity16. Once HA has bound to SA on the cell surface, the virion is taken into an 
endosome. Maturation of the endosome causes a decrease in the pH in the lumen, which in 
turn causes a conformational change in the structure of HA, exposing the fusion peptide. 
The fusion peptide extends into the lipid membrane of the endosome, and a second 
conformational change in the viral protein draws the two membranes together17. The viral 
capsid is released into the cytoplasm. Acidification of the endosome also allows hydrogen 
ions to enter the virus complex via the M2 ion channel, and this leads to the release of the 
viral RNP complexes from the capsid structure18.  
 
Following import of the viral capsid into the host cell cytoplasm, the RNP 
complexes are trafficked into the nucleus. The viral protein NP is critical to this process 
due to its nuclear localization signal (NLS). This process involves the exploitation of many 
host proteins, including the actin cytoskeleton for transport to the nuclear membrane. 
Import is governed by a class of proteins called alpha importins, which seem to be co-
opted by the RNP proteins through poorly-defined interactions19. 
 
 Once the RNP complex has entered the nucleus, the polymerase complex is free to 
initiate viral replication. The viral RNA dependent RNA polymerase has a dual function, to 
produce messenger RNA (mRNA) for protein expression, and the creation of new viral 
genomes (vRNA), two distinct processes20. mRNA synthesis is primer dependent, the PB2 
protein binds the 5' cap of a cellular mRNA21,22, which is subsequently cleaved by the PA 
protein23,24  and acts as a primer for elongation of the transcript by PB125 in a process 
known as “cap snatching”26. The mRNA acquires its polyadenylation tail by stuttering of 
the polymerase complex at a poly-uracil element at the 5' end of the segment27,28. Genome 
synthesis occurs by means of a positive sense complementary RNA template29. The 
process is primer independent, and does not involve the addition of the polyA tail to 
preserve genome integrity. The mechanism of switching from mRNA to vRNA synthesis is 
not well understood but has been suggested to involve accumulation of the NP protein30–32. 
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It has also been variously suggested to involve newly synthesized PA subunits33, NEP34 
and small non-genomic viral RNAs35.   
 
mRNA transcripts from the influenza genome require trafficking to the cytoplasm 
for translation by the host cell machinery into proteins. Some segments encoding more 
than one protein, e.g. segments 7 (M1 & M2) and 8 (NS1, NEP) require splicing by host 
proteins before being exported by the usual mRNA routes 36. Unspliced mRNAs usually 
are not permitted to leave the nucleus, but association with M1 seems to allow the genomic 
RNAs to exit the nucleus and join the assembly complex at the plasma membrane37,38. 
 
The M1 protein is hypothesized to be the main mediator of virus assembly, 
bridging internal gene segments and external envelope with glycoproteins39. One possible 
mechanism for this is association with the envelope glycoproteins within the Golgi body 
during traffic to the membrane40. HA and NA proteins are recruited to lipid raft structures41 
and are enriched on the membrane, which also contains many host proteins42. It is not 
certain whether the virus genome segments are packaged randomly43 or selectively by 
packaging elements, although there is increasing evidence for non-random models. 
Electron microscopy reveals an ordered arrangement of one central and seven surrounding 
segments44, possibly due to the action of specific packaging signals45,46. Once assembled, 
influenza virions bud from the apical surface of the host cell. For release of infectious 
virions, the NA must cleave SA on the envelope and emerging membrane to prevent virion 
clumping at the cell surface47. NA and HA must therefore work in a fine balance48.  
  
1.3.5 Influenza Ecology 
 
The natural reservoir of IAVs is assumed to be wild waterfowl, since with the 
exception of recently discovered bat-specific strains, most known subtypes have been 
isolated from these species. The virus replicates to high titre in the enteric tract of 
waterfowl, but seems to cause little observable clinical signs of disease49 . Faecal shedding 
leads to measurable virus levels in the water. Transmission between these animals is 
presumed to be from drinking this contaminated water and is highly efficient. Up to 30% 
of young ducks hatched in the spring test positive for IAV by the end of summer49. The co-
evolution of host and virus has been suggested to reduce virus pathogenicity for viruses of 
many different genera including IAV50 whereas novel viruses may be more destructive. 
Webster et al suggest that reduced pathogenicity may increase the virus transmission 
period and the number of hosts available, thus maximizing virus spread49. They observed a 
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much lower rate of IAV evolution in these wild waterfowl than in other infected species, 
and suggests that this indicates a virus that is already well adapted to this host species. 
Although initially questioned51, these results have been confirmed more recently by 
Fourment and Holmes52.  
 
However, IAVs periodically infect member other species that are exposed, leading 
to clinical disease, which is often fatal. Such spill over infections are observed in many 
species of birds and mammals, but are very limited in scope. Very infrequently, the 
influenza virus is able to replicate and transmit efficiently enough between members of the 
new host species to establish a novel IAV lineage. This has occurred in a limited set of host 
species including domestic poultry, humans, pigs, dogs and horses. Figure 1.4 shows 
hypothesized links between IAV lineages. 
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Figure 1.4: Schematic representation of Influenza transmission. Figure compiled of images in the public 
domain. 
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 Serological evidence indicates that the number of species exposed to influenza 
viruses in the environment is very high49. However, continuous lineages of IAV have only 
become established in a relatively small number of avian and mammalian species. Clearly 
contact with e.g. contaminated water sources is not sufficient for efficient IAV infection, or 
all species within these ecosystems would be infected. Instead, the host range is severely 
restricted; therefore there must be barriers to infection that exist at the host level and which 
restrict the pool of potential host species for the virus. In order for an IAV isolate to 
become established in a novel host species, it must circumvent these barriers and 
bottlenecks by a random process of opportunity and selection. 
 
1.3.6 Influenza Evolution 
 
For evolution to occur, there must be genetic variation within the virus population 
on which selective forces can act. Changes in the environment give an advantage to some 
members of a population over others, depending on their fitness in that new environment. 
Viral fitness has been defined as “the capacity of a virus to produce infectious progeny in a 
given environment” 53, although this does not consider the fitness element of transmission 
between host individuals. A more thorough consideration of fitness includes the ability to 
enter a host cell and replicate to high titre while avoiding neutralization by the intrinsic, 
innate and adaptive immune defences before being efficiently transmitted to a new host. 
 
Randomly generated changes in progeny virions compared to the original particle 
may affect the phenotype of the virus or have no effect. These changes may be neutral, or 
they may reduce the fitness of the progeny virus, e.g. with a nonsense mutation in an 
essential protein. These reduced fitness variants will not survive in the population, in a 
process known as purifying selection. Alternately, a random change to the virus genome 
may have a positive gain of fitness result. This may be an increase in enzyme activity, or 
escape from a restriction factor such as immune system components. Stochastically, viral 
variants with increased fitness will increase in frequency within the population. If the 
majority of the population carries the new genetic trait, it is said to have become fixed. The 
effect on fitness of a given change is highly context-dependent, a change which might 
evade human immune restriction is unlikely to help a virus circulating in chickens. There is 
therefore a highly random, probability basis of virus evolution. 
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IAVs employ two distinct mechanisms in the generation of genetic diversity, 
especially of the antigenic protein HA, which allow them to evade the antibody response of 
immunologically experienced hosts and allows re-infection, as well as generates a diverse 
population aiding in the infection of novel hosts. The rate of mutation in the viral genome 
is very high, up to 8e-3 nucleotide substitutions per site per year1, owing to the lack of 
proofreading of the viral RNA dependent RNA polymerase. This point change of the virus 
is known as genetic drift. The influenza A virus is able to derive an additional source of 
variation from the segmented structure of its genome. In a host infected with more than one 
strain, it is possible for the segments of different origins to be packaged into the same 
virion, in a process known as “reassortment”. This allows for the acquisition of traits as a 
block (e.g. a human adapted HA allowing an avian virus to enter human cells), causing 
large-scale changes to the virus known as genetic shift. Both mechanisms can lead to the 
establishment of a novel virus strain in a new host species. The 2009 pandemic H1N1 
strain emerged due to a triple reassortment of segments from avian, swine and human 
viruses, and spread rapidly across the world. Introduction of the H3N8 virus from horses to 
dogs was a whole virus with no reassortment, and therefore it can be assumed that 
adaptation to the novel host is by mutation alone. The ability to gain multiple adaptive 
mutations at once can make it difficult to determine which of them is most important. 
Studying single mutations that make large differences to viral fitness can be more 
informative about viral adaptive mechanisms. 
 
Studying host adaptive mutations provides vital insight into the mechanisms of 
viral emergence. However, this has some significant challenges. There is a wide range of 
possible host adaptive mutations, in many different areas, acting by any of multiple poorly 
understood mechanisms. These changes may occur in order to continue to exploit a host 
factor necessary for viral replication despite variation, such as the different SA linkages or 
alpha importins. Conversely, adaptation may be required to escape a host restriction factor 
that is different from, or absent in, the original host, e.g. MxA. Additionally, changes in 
replication conditions may require adaptation, as demonstrated by cold-adapted viral 
polymerases in the mammalian replication system. Many of these changes may be required 
to occur in a single virus for adaptation to a particular novel host species, making it 
difficult to identify the effect of any single mutation as they depend upon each other, 
exhibit synergism or exhibit other epistatic interactions. To further complicate the picture, 
any single mutation may alter multiple phenotypic characteristics. Pleiotropy, a single gene 
affecting multiple phenotypic traits, is common in viruses due to the small genome 
capacity.  Many viral proteins have multiple functions, more than one of which may be 
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influenced by an amino acid substitution; alterations in NP that increase alpha importin 
binding have been suggested to decrease polymerase activity19. In addition, proteins such 
as PA-X are expressed by frame shift from alternate reading frames within the coding 
region of the major proteins e.g. PA. This introduces an increased level of complexity as an 
adaptive mutation in one frame may affect (positively or negatively) the coding sequence 
of the other.  
 
A mutation that alters the viral action in the new host may or may not have arisen 
as a result of adaptation. It may have existed in the original host strain at low level and 
selected for in the new host, or it may have arisen after transmission to the new host and 
been required to establish a stable lineage. Mutations necessary for replication in the novel 
host, those required for establishment and those needed only to increase efficiency of viral 
production or transmission can also be differentiated54. In order to make these distinctions, 
carefully structured experiments at multiple levels are required. To determine the time 
point of mutation establishment, many samples from both host species at, before and 
following the transmission event are required to determine where it originates. 
Additionally, in order to determine the effects of mutations, measureable fitness 
determinants or proxy measurements are required in both hosts. These may be in vivo, or in 
vitro assays. 
 
1.4 Adaptation to a new host 
 
Sialic acid binding is a major host range determinant of influenza A viruses55. The 
avian gastrointestinal tract contains mostly α 2-3 linked SA with a narrower cone shape, 
requiring an HA with a similarly shaped binding pocket56. In the mammalian respiratory 
tract, the SA linkage is weighted in favor of the α 2-6 linkage, which is more umbrella 
shaped and so the HA of a mammalian influenza strains tends to have a wider binding 
pocket. The α 2-6 linkage is more prevalent in the mammalian upper respiratory tract, 
being the most susceptible to airborne infection, although the α 2-3 linkage is present, 
especially in the lower branches of the respiratory tract. Pigs have been reported as having 
the α 2-3 linkage in more accessible regions of their respiratory tracts, potentially allowing 
infection by avian-derived viruses and the establishment of a lineage in mammals. 
 
Nuclear import is governed by a class of proteins called alpha importins, which 
seem to be co-opted by the RNP proteins through poorly defined interactions19. This 
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appears to be an important barrier in host adaptation as the alpha importin proteins display 
a degree of species specificity. Mutations in both PB2 (701N) and NP (N319K) have been 
implicated in adaptation of the virus to increase efficiency of nuclear import in novel host 
species 19.  
 
1.4.1 Adaptation of the Polymerase Complex 
 
The action of the viral polymerase also depends on interactions with many host-
specific factors. One of the most significant of these appears to be the change in 
temperature in the mammalian respiratory tract (33 °C), as opposed to the digestive system 
of avian hosts (41 °C). Avian-adapted viruses display a reduction in polymerase activity at 
the lower temperature, although exactly which facet of polymerase activity or the 
mechanism by which this may occur is unclear. However, this phenotype seems to be 
reversed by a single mutation (E627K) in PB2 in many mammalian adapted viruses57. One 
notable exception to this is the 2009 pandemic H1N1 strain (pH1N1), which lacks this 
substitution. Other mutations in the polymerase complex seem to compensate, allowing 
increased activity via an alternate mechanism58.   
 
 Influenza viruses employ multiple mechanisms to evade the interferon response 
and prevent induction of an antiviral state in host cells. These mechanisms may also have a 
host-specific aspect. It has also been frequently noted that the NS proteins of different 
strains are responsible for differences in interactions with the host innate immune system. 
NS1 is an antagonist of the interferon response and has been shown to be vitally important 
in host adaptation59. Mutations in NP have been shown to ablate the binding of the Mx-A 
protein60, a species-specific interferon-stimulated restriction factor. 
 
1.4.2 Cold Adaptation 
 
Adaptation of the polymerase complex to maximize efficiency in the novel host has 
long been known to be a critical factor in IAV host range determination. Initial 
experiments of the 1970s outlined a “cold sensitive” avian influenza phenotype and a “cold 
insensitive” phenotype of mammalian adapted virus strains 61. This reflects the differing 
internal temperature in the avian enteric tract (41 °C) and the mammalian respiratory tract 
(33 °C) as sites for virus replication. Using recombinant viruses, Almond et al 61 were able 
to identify the PB2 subunit of mammalian origin as being responsible for producing a virus 
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able to replicate efficiently at 33 °C . Eventually, the single substitution of a lysine for a 
glutamic acid residue at position 627 of PB2 (E627K) was shown to be sufficient for the 
acquisition of the “cold insensitive” or “mammalian adapted” phenotype57. The mechanism 
of action of this substitution is not entirely understood. It has been suggested that it allows 
the polymerase complex to bypass a block at the level of vRNA synthesis15 although the 
relation to temperature is unclear. Intriguingly, the temptation to think of this substitution 
as a strictly mammalian adaptation seems to be flawed, as the E627K mutation is also 
required for the transmission of AIV strains from domestic poultry such as chickens to 
ratites62. Ostriches and their close relatives have a lower normal body temperature than 
other birds63, which may explain this observation.  
 
Although the E627K mutation has been shown to be sufficient to allow an avian 
polymerase complex to act efficiently in mammalian cells, it does not appear to be 
indispensible to do so. In 2009, the pandemic H1N1 strain (pH1N1) emerged from swine 
in Mexico64 as a triple reassortant virus, containing segments of classical swine (NP, M, 
and NS), human (HA, NA, and PB1), and avian (PB2 and PA) origins64,65. The PB2 gene, 
in accordance with its avian character, retained the glutamic acid at position 627 despite 
continued circulation in pigs and humans. The pH1N1 uses three compensatory mutations 
to get around this shortfall. Mehle et al demonstrated that what they called the “SR 
polymorphism” of PB2, a serine residue at position 590 and an arginine residue at position 
591, was able to relieve the restriction on 627E polymerase complexes and allow efficient 
replication15. They observe that these substitutions also give the net positive charge of the 
face of the PB2 protein also gained by 627K when present, and speculate that this may be 
of importance in interactions with other viral or host proteins. Additionally, an asparagine 
at position 701 has been shown to help compensate for the lack of 627K through a separate 
mechanism66.  
 
1.4.3 Virus Subunits 
 
Many identified adaptive mutations appear to affect the binding sites by which the 
complex’s subunits interact with each other. PB2 E627K has also been shown to increase 
the strength of the PB2-NP interaction, when paired with an avian NP 67–69. The advantages 
of increased bond strength specifically in mammalian host cells, as opposed to avian, are 
not immediately obvious. It has been suggested that tighter bonds may assist in creating a 
smaller target for RIG-I sensing 70 which may explain this disparity, since chickens and 
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related birds do not possess the RIG-I signalling pathway. In reassortants between equine 
and human influenza viruses, mismatch of PA lead to compensating mutations in PB2, 
restoring interaction and polymerase complex activity71.  
 
In the formation of reassortant viruses, virus segments from different parental 
viruses within the same cell are packaged together in the same virion. The non-random 
packaging model dictates that each segment is specifically incorporated by means of 
packaging signals in the UTR. Evidence suggests that the segments interact together to 
form a daisy-chain of bindings which are somehow incorporated into the virion matrix72. 
With segments of different parental viruses, mismatch in the UTRs and packaging signals 
disrupts this chain and no progeny virions can be formed. Restoring the UTRs to 
compatible versions restored infectivity. Thus, incompatibility of segment UTRs is a 
barrier to the formation of some combinations of reassortant viruses. 
 
1.4.4 Host Factors: 
 
Interactions with host cellular factors are a major driver of virus adaptation distinct 
from physical factors like temperature. These driving forces can act in either of two 
opposing directions. Viruses are obligate intracellular parasites and must make use of the 
host cell machinery during the replicative cycle to make genomes, proteins and acquire 
lipid bilayers. The inter-species variation of the components of this cellular machinery may 
require compensatory change in virus co-option mechanisms to allow the virus to replicate 
in the novel hosts. Alternately, the virus may need to change to avoid the host defences 
which act to restrict virus replication and spread. Components of the intrinsic immune 
system such as interferon signalling act within the cell to induce an “antiviral state” and are 
highly species specific.  
 
1.4.4.1 ANP32A 
 
In the case of interferon stimulated genes, it is clear that the restrictive factors are 
present and must be avoided for optimum virus function, however the case is not always so 
simple. It has long been observed that AIV polymerases, while fully functional in avian 
cell culture, have poor activity in mammalian cells73. It was initially unclear whether this 
was due to a restrictive factor present in mammalian cells but not avian cells, or the lack of 
a permissive factor in mammalian cells that was present in the chicken cell. In a seminal 
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experiment, Massin et al 74 engineered a fusion of an avian and a mammalian cell to 
examine the activity of the AIV polymerase. If the mammalian cell possessed a restrictive 
factor, this would still be present in the heterokaryon and the polymerase would not be 
active. If the mammalian cell lacked the permissive factor, this would be provided by the 
avian cell and polymerase activity would be restored. They demonstrated that the AIV 
polymerase complex was active in the heterokaryon. The permissive factor was 
subsequently identified by introducing a library of chicken genes into mammalian cells to 
try to rescue polymerase activity. The ANP32A gene is expressed in chickens as a longer 
form than the mammalian form which the AIV polymerase is unable to recruit75. It is not 
yet known what the function of ANP32A is in the virus lifecycle, however human-adapted 
influenza strains have adapted to recruit the shorter mammalian form, indicating its 
importance. The PB2 E627K adaptive mutation has been suggested to play a role in 
allowing recruitment of the short version of ANP32A75. Intriguingly, ratites also possess 
the shorter form of ANP32A.   
 
1.4.4.2 Importin α 
 
The best-characterised recruitment of host factors is the interaction of the 
polymerase proteins with the importin α family of proteins. IAV is remarkable among the 
RNA viruses for replicating in the nucleus of the host cell. In order to do this, the vRNPs 
must enter the nucleus to produce mRNAs which are trafficked to the cytoplasm for 
translation. The polymerase subunits return to the nucleus to repeat this cycle and increase 
production as well as being packaged into new virions. In order to cross the nuclear 
membrane, the virus proteins PB2 and NP make use of the classical nuclear import 
pathway by having a recognizable NLS19. This recruits the adapter protein importin α, 
which interacts with importin β and facilitates the complex crossing the nuclear pore. 
There are at least 6 isoforms of importin α, which are shared by chickens and humans with 
amino acid identity of 80-99% 76. Adaptation of AIV strains to mammals seems to involve 
a shift in dependency from importin α3 to importin α776.  Several mutations e.g. PB2 
D701N19,77 and NP N319K19,78 have been suggested to increase virus binding to 
mammalian importin α forms. PB1 and PA enter the nucleus as a dimer by a non-classical 
route involving RANBP579.  
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1.4.4.3 MxA 
 
The innate and intrinsic immune systems present a strong barrier which the virus 
must evade in order to become established in the novel host. The interferon signaling 
system activates a wide range of antiviral genes in response to infection, so IAVs have 
many strategies to down regulate or avoid these responses. MxA is an interferon induced 
dynamin-like GTPase first identified in 1961 as protecting one strain of mice from a 
usually lethal viral challenge in the laboratory80. The Mx family of GTPases is highly 
conserved in vertebrates, from birds and mammals to fish, but is inactivated by nonsense 
mutations or large deletions in most laboratory mouse strains81. In mouse strains with 
functional Mx1 (the homologue to human MxA) it acts within the nucleus to block the 
nuclear import and primary transcription of IAVs31. However, human MxA is cytoplasmic 
and blocks IAV replication at the stage of secondary transcription82. This appears to be due 
to the human MxA lacking an NLS, as when this is added the human protein localizes to 
the nucleus and blocks primary replication in the same manner as the mouse Mx180. 
 
Sensitivity to MxA restriction has been shown to be determined by the NP segment 
by using single segment reassortants of MxA sensitive and insensitive viruses in 
minireplicon83 and infection assays78. Zimmerman et al analyzed the sequences of MxA 
sensitive and insensitive NP to reveal candidate amino acid differences that may be 
responsible for this phenotype. The 1918 and 2009 pandemic H1N1 strains have been 
shown to have different amino acid signatures responsible for their MxA insensitive 
phenotypes84 however, the relevant amino acids cluster in a surface pocket in both cases85. 
This may give some insight into the mechanism of the antiviral effect of MxA. It seems 
that MxA binds somehow to the IAV polymerase, possibly NP, and blocks its function. 
Overexpressing the polymerase has been shown to overcome the MxA restriction 86 
presumably by titrating it out. Interestingly, overexpression of the PB2 subunit has been 
shown to have the same effect 87 although no direct interaction of MxA with PB2 has been 
demonstrated. The current model of MxA action is that it binds to the vRNP complex and 
oligomerises into a ring shape, preventing transcription of the viral RNA88. Adaptive 
mutations associated with avoiding MxA restriction presumably reduce MxA binding to 
NP, the principle protein component of the vRNP complex, although this has yet to be 
proven. Although most of this work has been done in humans and mice, horses have been 
shown to express two Mx-related proteins89 and that these have antiviral function90. 
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1.5 Influenza Virus Emergence 
 
IAV is an important threat to human and animal health due to its ability to jump 
between species. Emergence of new, animal-derived, lineages in humans may give rise to 
global pandemics as well as contributing to the seasonal influenza burden. Zoonotic 
introduction of viruses poses an especial threat to health due to the lack of immunity to 
these strains in the population, giving a large pool of susceptible individuals and allowing 
wider spread of the virus. 
 
1.5.1 Influenza Jumps to Humans 
 
The 1918 pandemic, which caused as many as 50 million deaths worldwide91 was 
derived from a circulating avian virus strain, although it is debated whether this was direct 
transmission92, through reassortment with circulating human strains93, or a similar 
reassortment event in swine94. The 1918 pandemic was particularly severe owing to the 
virus-induced induction of a cytokine storm in a high proportion of patients91. It is thought 
that adaptation of a pathogen to a novel host species over time tends to favour reduced 
pathogenicity, which may increase spread by increasing the time before the host becomes 
incapacitated95. This is illustrated by human influenza pandemics, which, after the peak 
number of infections, largely replace the prior circulating seasonal influenza strains. 
Increasing host immunity following exposure to the novel virus may also play a role. The 
1918 pandemic virus was sequenced by Taubenberger96, and had few mutations 
characteristic of human adaptation, being highly avian in nature except for the PB2 627K 
substitution97.  
 
Subsequent pandemic viruses, such as the swine-origin pH1N1 that caused the 
2009 pandemic, originated after complex reassortment events between birds, pigs, and 
humans. In the United Kingdom, there were approximately 29,000 confirmed cases of 
pH1N1, leading to 457 deaths98,99. Although this pandemic scenario was relatively mild, 
the UK government spent over £1.2 billion on vaccines and antiviral drugs, healthcare 
worker training and public information99. The impact on the British economy as a whole 
due to loss of earnings, decreased productivity and reduced confidence of such a pandemic 
has been estimated at £16 billion100. A pandemic scenario with a virus of similar lethality 
to the 1918 pandemic is anticipated to cause £78 billion in economic damage to the UK 
alone100. Interestingly, pH1N1 did not acquire the key mammalian-adaptive mutation PB2 
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627K. Three compensatory mutations in PB2 allow this virus to replicate efficiently in 
swine and human cells58.  
 
The World Health Organisation (WHO) defines pandemic risk from zoonotic IAV 
infection by a series of “phases” determined by the ability of a virus strain to infect and 
transmit among the human population101. A phase 1 virus infects animals only. A phase 2 
virus is capable of infecting humans in “spill over infections” from an animal host but not 
of human-to-human transmission. If the virus acquires this ability to cause short 
transmission chains or limited disease clusters, it is considered to be phase 3. Verified 
community level infection represents phase 4, at which point pandemic containment 
strategies and contingency plans are triggered. Phases 5 & 6 are defined by spread of the 
strain to multiple countries and multiple continents respectively. At the time of writing, the 
WHO has alerts active for several strains of avian influenza, including H5N1 and H7N9, 
that are circulating at a phase 2 or phase 3 level101. Human-to-human transmission is 
reported, although not verified in all cases, but sustained transmission chains do not appear 
to have occurred as yet.  
 
1.5.2 Influenza Species Jumps in Animals 
 
The introduction of animal influenza virus lineages into the human population is by 
no means a one-way street. In 1998, the circulating human H3N2 influenza strain became 
established in commercial pig farms6, causing widespread disease. It has since become 
firmly established to the extent that reassortants between the H1N1 and H3N2 have been 
reported102. This virus has also gone on to establish a distinct lineage in the novel host. 
 
There are multiple reported incidents of the transmission of avian influenza virus 
(AIV) isolates to mammals in a natural setting. In 1981, 400 harbor seals of all ages were 
found dead on the beaches of New England after suffering from a hemorrhagic 
pneumonia103. An H7N7 virus was isolated from these seals, which had many avian-like 
characteristics104, and was confirmed to be identical to local cases of “fowl plague” 
(AIV)105. Other influenza subtypes have since been identified in harbor seals, such as an 
outbreak of H10N7 in Sweden in 2014106 and H3N8 in New England in 2012107. These 
were shown to be separate introductions of avian-derived viruses into local seal 
populations. An H3N8 subtype AIV was also able to infect horses in the Americas in the 
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1960s and established a stable lineage108. This virus became sufficiently mammalian 
adapted to make the jump into dogs in 2003109.  
 
Increased understanding of the factors influencing host species jump events of 
IAVs is crucial to predicting them and taking measures to prevent outbreaks. The ultimate 
goal is to allow intervention at an early phase for IAVs with pandemic potential. This may 
be by surveillance to identify high-risk strains in nature e.g. by screening birds for phase 1 
strains with mammalian adaptive mutations. Containment measures such as quarantine 
zones and poultry culls can be enacted to reduce the threat of onward transmission. This 
information will also be of use in pandemic preparedness, e.g. in the development and 
stockpiling of vaccines against strains of concern as this can take up to a year.  
 
1.6 Equine Influenza 
 
1.6.1 Disease 
 
Influenza infections in horses manifest as infections of the upper respiratory tracts. 
They are characterized by clinical signs of fever, nasal discharge, hacking cough, loss of 
appetite and tracheobronchitis over a period of five to ten days110. Although mortality is 
low (less than 10% in most outbreaks), advice from the Merck Veterinary Manual111 is to 
rest the animal for a minimum of one week after the end of signs. Other horses in the same 
stable are usually also quarantined to prevent a wider outbreak of disease. This has a 
significant cost to working animals such as racehorses, where the animals can neither race 
nor train for a period of several weeks. A recent outbreak of suspected equine influenza 
virus in Newmarket in September 2016 closed six stables and was estimated to cost the 
horse racing industry £100,000 in lost winnings and race-track betting112, although no 
cases of influenza were confirmed.  
 
1.6.2 EIV Lineages 
 
IAVs have become established in horses, presumably from an avian reservoir, at 
least three separate times in the past century to give separate equine influenza virus (EIV) 
lineages. The first EIV was isolated in 1956113, although similar disease has been reported 
in horses since at least the Victorian era and possibly much earlier114. The virus isolated in 
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1956 was an H7N7 virus that infected horses in Prague and central Europe in the 1950s. 
The H3N8 EIV lineage is estimated to have emerged in horses in the mid 60s from an 
avian reservoir 115 although it is not possible to pinpoint the exact transmission event. It co-
circulated with the previously existing H7N7 EIV until the late 1970s, however the H7N7 
EIV has not been isolated since 1980 and is now considered to be extinct116. These equine 
influenza strains cause respiratory disease in horses although mortality rates are low117. 
However, in 1989 a distinct H3N8 virus emerged in horses in the Chinese province of Jilin 
with a high mortality rate of up to 40%115. This was subsequently shown to be a novel 
introduction of an avian H3N8 virus to mammals115. However, this virus did not persist in 
the population, circulating the following season with reduced mortality and not detected in 
the third season 116. The 1989 Jilin virus was also shown to cause disease in mice and 
ferrets, although it had lost the ability to replicate in ducks, its proposed original host 
species 118.  
 
So called “classical” H3N8 EIVs have become well established in the equine 
population and continued to circulate for the past 50 years despite the availability of 
vaccines. Vaccination of the horses does not seem to produce a sterilizing immunity, there 
is still the possibility of subclinical infection which aids the virus to spread to a naïve herd. 
The H3N8 lineage is divided by geographical area of incidence into two main lineages, the 
Eurasian and American lineages. The American lineage is further subdivided into the 
Florida clades 1 and 2119. The EIV lineage is intriguing in retaining many signatures of 
avian-adapted viruses despite many years circulating in the equine population with 
efficient replication and transmission. The HA of H3N8 EIV retains a bias towards 2,3 
linked SA residues, as this is the predominant linkage found in the horse trachea120. The 
adaptation mechanism of the polymerase complex is especially interesting as it has 
acquired neither the common PB2 627K mutation, nor the compensatory trio of mutations 
seen in pH1N1. Mammalian-cell adaptation appears to be by an unknown mechanism. 
 
1.6.3 Canine Influenza Emergence 
 
In 2003, influenza emerged in dogs with significant disease and approximately 40% 
mortality rate associated with respiratory haemorrhage109. The virus strain responsible was 
isolated, examined and determined to be very similar to an H3N8 Florida clade 1 EIV 
circulating at the time, with 96% identity at the nucleotide level. This indicated that the 
canine virus was a direct descendant of the equine strain. Transmission is believed to have 
 Page 24 
 
occurred at shared racehorse and greyhound race tracks, where the two species have a high 
level of contact 109. Canine Influenza Virus (CIV) has formed a stable lineage distinct from 
EIV, and no longer efficiently infects horses121. It has since been isolated from dogs in 
North America and Europe, particularly in kennels and high density populations. 
 
1.6.4 EIV as a Model Virus 
 
The classical EIV lineage is of particular interest in studying host adaptation because 
it appears to have been a direct interspecies transfer of an intact virus 109 first from an avian 
to a mammalian host, then between mammalian species. Changes in EIV over time from 
the 1960s to 2004 may have increased the likelihood of a transmission event into a novel 
mammalian host. The transmission between mammalian species that are not closely 
related, as distinct from a transmission event from an avian reservoir, may provide a better 
model of risk factors for species jumps into humans from other mammals (such as swine).  
 
1.7 Experimental Approaches in this Study. 
1.7.1 Equine Tracheal Explants 
 
Ex vivo organ culture is a widely used method to study viral replication in a more 
physiologically relevant system than cell culture. The tracheal explant system is the closest 
model system to the whole organism available to us for laboratory study122. Use of ex vivo 
organ cultures is encouraged by the Home Office in line with the “3Rs” ethos of reducing, 
replacing and refining live animal studies wherever possible. There are also logistical 
advantages over infectious studies of large animal such as horses, which require 
specialized facilities, although inter-host transmission cannot currently be studied in the ex 
vivo system. 
 
To this end, the Murcia lab has previously established an equine tracheal explant 
culture system based on the swine tracheal culture system developed by Filipe Nunes in his 
doctoral thesis123,124. Sections of tracheal epithelial tissue are maintained in culture at the 
air-liquid interface for up to 12 days. These sections can be exposed to virus challenge and 
a phenotype of viral infection determined125. They contain all of the cell types naturally 
found in the tracheal tissue, such as ciliated and non-ciliated epithelial cells, goblet cells, 
and fibroblasts which may be an advantage over traditional infection assays of 
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monocultures of cells in vitro in determining a more physiological response to infection 
challenge. The tracheal explants also contain cells of the innate immune system such as 
macrophages and eosinophils which are involved in early stages of the response to viral 
challenge. 
 
.The tracheal epithelium is a pseudo-stratified ciliated columnar epithelium made 
up of several specialised cell types. At the epithelial surface are the ciliated cells, which 
beat the cilia in a coordinated wave to remove inhaled particulates and pathogens from the 
respiratory tract. Goblet cells produce mucous which traps the particles as part of the 
muco-ciliary escalator system. Also present in small numbers are immune cells such as 
eosinophils. Basal cells make up the bulk of the epithelial layer. Beneath the epithelial 
layer, the lamina propria is a loose cell rich connective tissue containing many capillaries 
that provide nutrients to the epithelium. The submucosa supports the epithelial layer and is 
a denser connective tissue with many elastic fibres to assist in recoil during respiration. 
This layer is separated from the underlying cartilage in explant preparation. 
 
The tracheal explant system does not contain the elements of the adaptive immune 
system, such as cytotoxic T cells and virus-specific antibodies which would ordinarily be 
recruited in response to the viral challenge. However, some mucosal antibodies or memory 
B cells may remain, as explants from vaccinated horses, or ones whose immunostatus is 
unknown, have proved refractory to virus infection (Gonzalez, Chauche unpublished data). 
Chambers et al126 have suggested that this lack of adaptive immunity makes the tracheal 
explant system a weaker model of viral fitness in the host. In these experiments, viruses 
able to replicate in the tracheal explant system were not found to infect horses efficiently 
or to transmit between horses. However, as a system to examine the efficiency of virus 
replication in a physiological set up, distinct from transmission and immune evasion, the 
tracheal explant system is unsurpassed.  
 
1.7.2 Reverse Genetic Virus Systems 
 
In the reverse genetic virus, virus proteins and the RNA genome are expressed from 
plasmids that are transfected into host cells. These components use the viral self-assembly 
mechanisms to form virions exactly as in a natural infection. Infectious virions are released 
into the supernatant by budding from the host factory and can be recovered and passaged 
as any viral stock.  This is termed “virus rescue”. The reverse genetic virus approach 
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allows manipulation of the virus at the genome level, and identification of individual genes 
responsible for phenotypic traits. The genome of the virus can be altered by altering the 
plasmids transfected for the rescue with common molecular techniques. With this 
technique it is also possible to produce a nearly clonal virus population, rather than the 
dispersed cloud of quasi-species generally found in natural isolates. This molecular 
flexibility is key to the elucidation of specific adaptive mutations.  
 
The first published influenza reverse genetic system by Neumann et al in 1999127 
comprised 16 separate plasmids. Eight plasmids were used to express the eight RNA 
segments of the influenza virus genome, and eight to express the essential virus protein 
expressed from each plasmid. The protein-producing and RNA-producing plasmids were 
in the opposite “senses”, to produce positive sense mRNA for protein synthesis and 
negative sense viral RNA, and were under the control of different promoters. Virus 
proteins were expressed from a well-characterised chicken β actin promoter and poly 
adenylation signal. However, vRNA production was more complicated. The IAV 
polymerase will not tolerate additional nucleotides at the termini of the RNA segment 128. 
If any nucleotides are added, the polymerase complex cannot bind to the UTR, which acts 
as the viral promoter, and neither mRNA nor vRNA can be produced. For this reason, the 
vRNA-producing plasmids were initiated by the RNA polymerase I promoter, which has a 
highly defined transcriptional start site129. Neumann et al used an RNA polymerase I 
terminator to give the transcript a defined termination signal130. An alternate approach used 
by Engelhardt et al131 was to include a ribozyme sequence at either end of the viral 
segement. When this was transcribed to RNA, the folding of the sequence was able to 
catalyse a strand break at the precise point to give the viral RNA with correct UTRs and no 
additional nucleotides. However, this proved less successful than the promoter-terminator 
approach, and most subsequent systems use the RNA polymerase I approach. 
 
The 16 plasmid system proved to be somewhat unwieldy as for a cell to produce 
infectious virus it had to acquire every plasmid. Co-transfection of this many plasmids 
proved inefficient, as might be predicted using the Poisson distribution. In the interests of 
increasing the efficiency of virus rescue, Neumann published a refinement of the IAV 
reverse genetic system in the same year127. This was to use only 12 plasmids, the eight 
RNA-producing ones, and four protein-expression plasmids. If the proteins comprising the 
viral polymerase complex (PB2, PB1, PA and NP) were expressed alongside the vRNA, 
the viral polymerase was capable of expressing the other required proteins from the viral 
genomic segments. This is more similar to a natural infection whereby the incoming virion 
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introduces its genome into the host cytoplasm with the polymerase complex attached and 
the complete virus replication cycle can occur.  
 
Hoffman et al132 have developed a system with fewer plasmids still., as shown in 
Figure 1.5. This system requires only eight plasmids, however each must express both 
negative sense RNA viral genomes and positive sense mRNA for protein synthesis. This is 
achieved by two sets of promoters and terminators flanking the viral genomic sequence 
and acting in different directions. The RNA polymerase 1 promoter and terminator are 
positioned exactly at the ends of the UTRs as described above to give a negative sense 
genomic transcript with nucleotide exact ends. Beyond the RNA polymerase I terminator 
sequence, the chicken actin promoter produces mRNA in the opposite direction. The 
mRNA transcript will contain the pol I terminator, the virus gene sequence and the pol I 
promoter before reaching the polyadenylation signal at the other side of the RNA-
producing cassette. Since the ribosome can bind any mRNA it encounters, but will not 
initiate translation until it reaches the start codon, only the viral gene will be expressed in 
the polypeptide chain. Thus both vRNA and protein can be expressed from the same DNA 
sequence. Since there are fewer plasmids to co-transfect, the virus rescue efficiency of this 
system is higher than that of previous systems. The ease of creating virus mutants via site-
directed mutagenesis and recombinant virus strains by selecting plasmid segments from 
more than one parent strain continues to make the Hoffman reverse genetic system 
popular.   
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A      B 
 
Figure 1.5: Dual sense eight plasmid reverse genetic virus rescue system. A) The vRNA and mRNA are 
expressed from the same gene segment by different promoters. B) Sets of eight plasmids are transfected into 
target cells to give infectious virus. Plasmid sets may be mixed to give rise to reassortant viruses. 
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Virus rescue has also been demonstrated from a single bacmid encoding all of the 
virus segments133, but the size of this construct limits its uptake by mammalian cells. Using 
this system to rescue reassortant viruses requires another construct to be created, limiting 
the flexibility of use. Perez et al134 have demonstrated rescue of virus from transfected 
PCR products, bypassing the need to clone into plasmids, although the efficiency of rescue 
is still low. They has also published on the rescue of viruses from plasmids aerosolised into 
the nasal epithelium of ferrets, without passaging the virus beforehand in cells or eggs, to 
reduce the adaptive bias this creates.  
1.7.3 Minireplicon Assay 
 
The minireplicon assay is used to measure the activity of the viral polymerase in an 
in vitro system. This assay uses a reporter gene such as luciferase in a synthetic negative 
sense RNA “gene segment” with viral promoters. The virus polymerase is able to 
recognise these elements to bind and transcribe luciferase mRNA which is translated to 
protein by cellular ribosomes. On cell lysis and addition of substrate, the emitted light is a 
measure of the amount of luciferase present which correlates with amount of mRNA 
present and so can be taken as a proxy of polymerase activity.  For ease of transfection, the 
reporter segment is introduced as a DNA plasmid with a cellular promoter and terminator 
to express the RNA template. The influenza viral polymerase will not tolerate the addition 
of even a single base to the viral promoters128 so the transcription from DNA to RNA must 
be exact. A schematic of the minireplicon system is shown in Figure 1.6. 
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Figure 1.6: Minireplicon assay schematic. Blue lines represent plasmid DNA arrangement. Green 
indicates RNA and red indicates the protein product. Yellow star indicates light produced on addition of luciferase 
substrate. The negative sense luciferase is flanked in the plasmid by IAV segment 8 UTRs, outside of which are the 
host RNA pol I promoter & terminator. The action of the RNA pol I generates a negative sense RNA analogous to an 
influenza genomic RNA segment. This is recognised by the viral polymerase complex which binds to the UTR 
panhandle structure, and is used as a template to generate mRNA for translation to protein by the ribosome. On 
addition of luciferase substrate the enzyme, the light emitted is quantified as a correlate of polymerase activity. 
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The cellular RNA polymerase I (RNA polI) has a defined transcriptional start site 
(TSS) and termination site so is ideal for this assay. The promoter sequence of RNA pol I 
is species specific due to the binding capability of one of the accessory proteins, TIF-IB135, 
and the variability is high. A reporter with the correct RNA pol I promoter is required for 
each species to be tested.  The reporter for the easily transfectable human 293T cell line is 
well described74,136. Reporters for chicken128, swine137 and canine138,139 derived cell lines 
also exist. Very little work has been done with equine-derived cell lines so no equine 
reporter existed prior to this study. Helpfully, the murine derived terminator sequence is 
compatible with multiple cell lines140. 
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2 Aims: 
 
2.1 Research Question 
 
• How do avian-origin influenza viruses adapt to mammal hosts? 
 
2.2 Research Aims 
 
• Define the phenotype of infection of a panel of evolutionarily distinct EIVs 
to look for evidence of adaptation, in equine tracheal explants (Chapter 4). 
• Define infection phenotype in vitro using avian and mammalian cells and 
compared with results obtained in previous aim (Chapter 5). 
• Generate reverse genetic plasmid sets as molecular tools to investigate the 
role of individual segments (and mutations in them) in mammalian 
adaptation (Chapter 5). Focus was on the virus polymerase segments, 
especially PA, due to its high evolutionary rate. 
• Develope in-vitro polymerase function assay for equine cells (Chapter 6). 
• Investigate the role of the viral polymerase in mammalian adaptation on 
molecular level (Chapter 6), including the role of specific mutations. 
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3 Materials & Methods 
 
3.1 Cells 
 
Human embryonic kidney (293T) cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco) supplemented with 10% Foetal Calf Serum (FCS, 
Gibco) and 1% penicillin-streptomycin (Gibco). Equine dermal fibroblast (E Derm ATCC-
CCL-57) cells were cultured in DMEM, supplemented with 15% FCS, 1% penicillin-
streptomycin, 1% L-glutamine (Gibco) and 1% non-essential amino acids (Gibco). Madin-
Darby Canine Kidney (MDCK) cells were cultured in Minimal Essential Medium (MEM, 
Gibco) supplemented with 10% FCS, 1% L-glutamine and 1% penicillin-streptomycin. 
Chicken fibroblast (DF-1) cells were cultured in DMEM (Gibco) supplemented with 10% 
FCS (Gibco) and 1% penicillin-streptomycin (Gibco). All cells were cultured in humidified 
incubators at 5% CO2 at 37 °C, except for DF-1 cells which were grown at 39 °C.  
 
3.2 Viruses 
3.2.1 Virus isolates 
 
Strain Abbreviation Origin 
A/Equine/Uruguay/1963 Uruguay/63 NIMR collection 
A/Equine/Sussex/1989 Sussex/89 Animal Health Trust 
A/Equine/Ohio/2003 Ohio/03 University of Kentucky 
A/Equine/South Africa/2003 SouthAfrica/03 NIMR collection 
A/Equine/Mongolia/3/2013 Mongolia/03 State Central Veterinary 
Laboratory (Mongolia) 
A/Northamptonshire/2013 Northamptonshire/13 Animal Health Trust 
A/Avian/Mongolia/80/2013 AIV80 Faecal isolate 
 
Table 3.1: Virus Isolates 
  
Virus isolates were grown in embryonated hens eggs.  
3.2.2 Sequence Analysis 
 
Viral RNA was extracted using the QiaAMP viral RNA mini kit (Qiagen) and 
reverse transcribed using the Common_Uni-12 primer141 and SuperScript Platinum One 
step RT PCR kit (Thermo-Fisher). RT-PCR protocol is detailed under whole genome 
amplification below. 
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 Library preparation and Illumina MiSeq sequencing was performed by Gaelle 
Gonzalez and Gavin Wilke. Consensus sequences were assembled by Henan Zhu. The 83 
full genome EIV sequences existing on GenBank were downloaded and added to the 
dataset. Phylogenetic analysis was performed in MEGA 7 for each segment. Coding 
regions for each segment (PB2 2,277 nucleotides, PB1 2,271 nucleotides, PA 2,148 
nucleotides, HA 1,701 nucleotides, NP 1,494 nucleotides, NA 1,410 nucleotides, MP 756 
nucleotides, NS1 657 nucleotides) were aligned using MUSCLE (Codon) with the 
UPGMB cluster method for 8 iterations. The evolutionary history was inferred using the 
Neighbor-Joining method142. The evolutionary distances were computed using the 
Maximum Composite Likelihood method143 and are in the units of the number of base 
substitutions per site. The analysis involved 97 nucleotide sequences. All positions 
containing gaps and missing data were eliminated. The robustness of individual nodes was 
assessed by a boot-strap resampling process (1,000 replicates) using the Neighbour-Joining 
method that included the ML substitution model. All evolutionary analyses were conducted 
in MEGA7144.  
 
3.2.3 Primer Sequences:  
 
Primer Name Sequence 
Common_Uni 12 GCCGGAGCTCTGCAGATATCAGCAAAAGCAGG 
Common_Uni 12G GCCGGAGCTCTGCAGATATCAGCGAAAGCAGG 
Common_Uni 13 GCCGGAGCTCTGCAGATATCAGTAGAAACAAGG 
 
Table 3.2: Primer Sequences for Universal Virus Amplification 
 
3.2.4 Reverse Genetic Viruses 
 
The Ohio/03 reverse genetic plasmids set in the pDP2002 dual sense vector were 
kindly provided by Daniel Perez (University of Georgia). Novel reverse genetic virus 
plasmids were created by cloning viral segments from isolates into the dual sense vector 
pDP2002 in the manner described in Hoffman et al (2001)145, which is briefly described 
below. 
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3.2.4.1 RNA extraction and cDNA generation 
 
Briefly, RNA was extracted from 140ul virus stock using the QiaAMP viral RNA 
mini kit (Qiagen) and reverse transcribed using the Common_Uni 12 primer (sequence as 
above) and AccuScript Reverse Transcriptase (Promega). An aliquot of 4µl of extracted 
viral RNA was incubated with 1µl 10mM Uni12 primer at 70 ºC for five minutes to allow 
primer binding before being cooled to 4 ºC. Then, 1 unit AccuScript polymerase, 2 µl 
10mM dNTP mix (Invitrogen), AccuScript buffer to 1x, MgCl2 to 10mM, were added 
according to the manufacturer’s instructions. 40 units RNAseOUT (Invitrogen) were also 
added to the reaction mixture. The thermocycler program was as follows: 90 minutes at 42 
ºC for reverse transcription, followed by 10 minutes at 70 ºC to inactivate the AccuScript 
and RNAseOUT enzymes. The reaction was cooled to 4 ºC. 
 
3.2.4.2 Whole Genome Amplification 
 
From the cDNA template, a whole genome amplification polymerase chain reaction 
(PCR) reaction was performed using the PFU Ultra II Fusion HS polymerase (Agilent). 
The reaction mixture contained 1 unit PFU Ultra II polymerase, and PFU Ultra II buffer to 
1x, 2 µl 10mM dNTP mix, 1.5 µl of forward primer Common_Uni 12 or Common_Uni 
12G and 1.5 µl of reverse primer Common_Uni-13. The template was 1 µl cDNA 
unpurified from earlier cDNA synthesis. The thermocycler program is displayed in Table 
3.3 . 
 
 
94°C 4 min  
94°C 30 sec 
X5 45°C 30 sec 
72°C 7 min 
94°C 30 sec 
X35 55°C 30 sec 
72°C 7 min 
72°C 10 min  
4°C Hold  
 
Table 3.3: Virus amplification PCR cycling parameters 
 
PCR product was purified using the Qiagen PCR purification mini kit according to 
the manufacturer’s specifications. Each segment was amplified in a secondary PCR 
reaction using segment specific primers containing BsmBI or BsaI restriction sites. Virus 
sequence was inspected for BsmBI and BsaI restriction sites using the NEBcutter online 
tool 146 and the more suitable restriction enzyme selected. Where necessary, if the sequence 
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contained a BsmBI recognition site, the primers published by Hoffmann et al145  were 
altered to include the alternate restriction site to create a second, alternate set of primers. 
 
Segment Enzyme Forward Primer Sequence Reverse Primer Sequence 
PB2 BsmBI TATTCGTCTCAGGGAGCAAAAGCAGGTC ATATCGTGTCGTATTAGTAGAAACAAGGTCGTTT 
BsaI   ATTGGTCTCAGGGAGCGAAAGCAGGTC ATATGGTCTCGTATTAGTAGAAACAAGGTCGTTT 
PB1 BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGCA ATATCGTCTCGTATTAGTAGAAACAAGGCATTT 
PA BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGTAC ATATCGTCTCGTATTAGTAGAAACAAGGTACTT 
BsaI TATTGGTCTCAGGGAGCGAAAGCAGGTAC ATATGGTCTCGTATTAGTAGAAACAAGGTACTT 
HA BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGGG ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT 
NP BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGGTA ATATCGTCTCGTATTAGTAGAAACAAGG 
NA BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGAGT ATATCGTCTCGTATTAGTAGAAACAAGGAGTTTTTT 
BsaI TATTGGTCTCAGGGAGCGAAAGCAGGAGT ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT 
M BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGTAG ATATCGTCTCGTATTAGTAGAAACAAGGTAGTTTTT 
NS BsmBI TATTCGTCTCAGGGAGCGAAAGCAGGTAG ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT 
 
Table 3.4: Segment specific sequences for viral amplification. Bold face type indicates region is 
complementary to viral UTR. Normal type indicates region containing restriction site. The alternate primer sets are 
indicated as BsmBI or BsaI accordingly.  
 
For the secondary PCR, 1 µl purified PCR product from the whole genome 
amplification was used as a template. The three large polymerase segments were amplified 
from the Uni12G reaction, while the other five were amplified from the Uni12 reaction. 
PCR conditions were as above. PCR products were analysed by gel electrophoresis on 1% 
agarose gel with ethidium bromide. Desired bands were excised and gel purification 
performed using the Qiagen Gel Extraction mini kit according to the manufacturer’s 
specifications.  
 
Alternatively, virus segments were synthesised (GenScript), including restriction 
sites and entered the pipeline at this point. Up to 20 µl of gel extraction product or 
synthesized virus segment was digested with 2 units BsmBI or BsaI (NEB) for 4 hours at 
37 ºC (BsaI) or 55 ºC (BsmBI) in a waterbath. 3µg of the plasmid vector pDP2002 was 
digested similarly with BsmBI. Reactions were purified as above. The digested vector was 
dephosphorylated with 5 units calf intestinal alkaline phosphatase (NEB) for 1 hour at 37 
ºC in a waterbath. Reaction was purified as above. Ligation reactions contained 50 ng 
digested dephosphorylated pDP2002, and insert in the ratio 1:5 of molar free ends, with the 
1.5 units T7 ligase (NEB) and were incubated for 16 hours at 4 ºC. 5 µl of ligation reaction 
was used to transform TOP10 competent bacteria (Invitrogen) according to the 
manufacturer’s recommendations.  
 
 
 Page 37 
 
3.2.5 Virus Rescue 
 
A 2:1 coculture of 293T:MDCK cells was grown to a total of 2e5 cells per well of a 
6 well plate. The following day, growth media was replaced by 1ml OptiMEM (Gibco). 
312 ng of plasmid encoding each virus segment (PB2, PB1, PA, HA, NP, NA, M and NS) 
were transfected using the TransIT-LT1 transfection reagent (Mirus). After 24hr the 
transfection mix was removed, and replaced with DMEM + 1 µg/ml TPCK treated trypsin 
and 0.3% bovine serum albumin (BSA). Cells were monitored for cytopathic effect (CPE) 
for up to 5 days, collecting supernatant once 70% of cells had died.  
 
3.2.6 Plaque Assays 
 
100µl of ten-fold dilutions of viral stock in infection media were used to infect 
confluent MDCK cells in a 48 well plate. Dilutions from 10^-1 to 10^-8 were applied in 
triplicate. One hour post infection the cells were washed with Phosphate Buffered Saline 
(PBS) and an overlay of 1:1 2x MEM (Gibco) and 2.4 % Avicel (FMC biopolymer) 
mixture with 0.1% TPCK treated trypsin applied. After three days, the overlay was 
removed, the cells washed three times in PBS and fixed in ice cold 80% acetone for 10 
minutes. The plates were dried overnight, permeabilised in 50µl PBS with 1% Triton X100 
for 10 minutes, blocked with 50µl PBS with 0.3% Tween 20 and 10% NGS for 30 minutes. 
Plates were immunostained using an anti-NP mouse monoclonal antibody (European 
Veterinary Laboratory, clone HB65) diluted 1:1500 in PBS with 0.3% Tween 20 
(PBST)and 10% NGS at 4 ˚C overnight. After 3 washes in PBS, a secondary anti-mouse 
antibody (clone HB65; dilution, 1:1500; European Veterinary Laboratory) coupled to the 
horseradish peroxidase enzyme, in 5% NGS in PBST for 1 hour. The plates were washed 3 
times in PBS, and 50µl of the true blue stain (Invitrogen) was added and developed for ten 
minutes to allow visualization of infectious foci. Foci were counted at the lowest dilution 
where distinct foci were visible and not overlapping. The mean number of foci from the 
three wells was taken and used with the dilution factor (e.g. 10-6) to calculate the foci 
forming units per millilitre according to the equation: 
 
Titre (ffu/ml) = mean foci number / (dilution factor x infection volume) 
 
The titre of focus forming units was assumed to be equivalent to plaque forming 
units (pfu) as initial experiments with CPE-producing viruses gave no difference in clear 
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plaques of CPE as visualised by crystal violet, and focus forming units visualised by this 
method.  
3.2.7 Experimental infections 
 
Confluent monolayers of MDCK, DF-1 or E derm cells in a 12 well plate were 
counted to calculate a multiplicity of infection (MOI). Wells were infected in triplicate 
with an MOI of 0.1 or 0.001 of each virus or mock infected. After 1 hour, the inoculum 
was removed, the cells washed and overlaid with 500 µl infection media. For MDCKs this 
was DMEM + 1 µg/ml TPCK trypsin and 0.3% BSA, for DF-1s DMEM + 0.5 µg/ml 
TPCK trypsin and 0.1% FCS. E derms were overlaid with growth media DMEM + 15% 
FCS + 1% Non-Essential Amino Acids. Supernatant was collected for virus titration and 
cells collected by trypsination for Flow Assisted Cell Sorting (FACS) analysis. 
 
3.2.8 FACS 
 
Trypsinised cells were fixed in 1% formalin overnight, permeabilised in PBS with 
0.1% Triton X100 for 10 minutes, blocked with PBS with 0.3% Tween 20 and 10% 
Normal Goat Serum (NGS) for 30 minutes. Cells were immunostained using an anti-NP 
mouse monoclonal antibody  (European Veterinary Laboratory, clone HB65) diluted 
1:1500 in PBST with 0.3% Tween 20 and 10% NGS at 4 ˚C overnight. After three washes 
in PBS, a secondary anti-mouse antibody coupled to Alexafluor 488, diluted 1:2500 in 5% 
NGS in PBST for one hour. Counting of stained cells was accomplished on the Accuri C6 
Sampler flow cytometer for 10,000 events. 
 
3.3 Horse Tracheal Explants 
3.3.1 Preparation & culture 
 
Equine tracheas were collected from two Dartmoor ponies culled due to congenital 
heart defects, aged 2 years. Naivety to EIV infection was determined by lack of antibody 
titre by haemagglutination inhibition (HAI). Tracheas were aseptically collected 
immediately upon euthanasia and transported in prewarmed medium consisting of a 1:1 
mixture of Dulbecco modified Eagle's medium (DMEM) and Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with penicillin (100 U/ml; Gibco, Life 
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Technologies), streptomycin (100 µg/ml; Gibco, Life Technologies), and fungizone (2.5 
µg/ml; Gibco, Life Technologies). Tracheas were kept at 37°C, 5% CO2, and 95% 
humidity. The culture medium was replaced six times over a period of 4 hours to remove 
microbiota. 
  
After washing, the tracheas were opened lengthwise and the epithelial mucosa 
removed from the underlying cartilage. This was then cut into approximately 0.5- by 0.5-
cm explants and placed with the epithelium facing upwards onto a sterile section of filter 
paper that was in turn placed onto agarose plugs for structural support in six-well plates. A 
thin film of medium covered the filter paper and the basal portion of the explants, as 
described in Nunez et al (2009)123, mimicking the air interface found in the respiratory 
tract of the living animal. Explants were maintained at 37°C, 5% CO2, and 95% humidity 
for up to 7 days. Steps can be seen in Figure 3.1. 
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Figure 3.1: Equine tracheal explant preparation. A) Washing steps. B) The trachea was opened 
lengthways and cut in half C) Each tracheal ring was sectioned and further subdivided into six explants (D). E) 
Explants were cultured at the air-liquid interface. Figure adapted from Livia Patro (thesis) with thanks. 
 
  
A B C 
D E 
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Explants were infected with 200 pfu of each virus suspended in 1:1 DMEM:RPMI 
media (as above) at 24 hours post sectioning, or mock infected. Samples were collected 
every 24 hours post infection. To assess the kinetics of virus growth, the explant was 
immersed in 500 µl PBS (Gibco, Life Technologies) and vortexed for 5 minutes. 
Supernatant was titrated for virus yield as above. Explant samples for histology were 
placed in 10% buffered formalin overnight before transfer to ethanol solution.  
 
3.3.2 Assessment of viability of organ culture by ciliary beating 
 
Ciliary beating of the tracheal explants was checked every 24 hours post infection. 
Two microliters of an emulsion of polystyrene microsphere beads (Polysciences, 
Northampton, UK) was placed onto the apical surface of the explants. Bead clearance was 
checked by eye every 5 minutes. The assay was considered completed when the beads 
were completely cleared to one side of the explants by coordinated cilia movement. 
3.3.3 Haematoxylin & Eosin (H&E) and Immunohistochemical (IHC) staining 
 
After collection, the explants were fixed in 10% (vol/vol) buffered formalin. 
Samples were submitted to the University of Glasgow internal histology service for 
embedding in paraffin and slide preparation of 4µm sections. These were subjected to 
haematoxylin and eosin staining by the histology department or immunohistochemical 
staining by myself. Antigen retrieval was performed using citrate buffer followed by 
pressure cooker heating. Sections were incubated in a peroxidase-blocking buffer (Dako 
EnVision) for 10 minutes and incubated overnight at 4°C either monoclonal mouse anti-
NP (dilution, 1:400; clone HB65, European Veterinary Laboratory) or monoclonal rabbit 
anti-cleaved caspase 3 (dilution, 1:800; Cell Signalling) diluted in 10% NGS. 
Immunohistochemistry was performed using the Dako EnVision system according to the 
instructions of the manufacturer, and slides were counterstained with Mayer's hematoxylin. 
Histological images were captured using cellDˆ software (Olympus). 
 
3.4 Minireplicon Assays 
 
293T or DF-1 cells were seeded at 5x105 cells/well in 12-well plates, E derm cells 
were seeded at 7x104 cells/well. They were transfected at 80-90% confluency 
(approximately 24 hours post plating) with plasmids encoding the PB1 (160 ng), PB2 (160 
 Page 42 
 
ng), PA (40 ng) and NP (320 ng) genes of each virus, alongside 160 ng of a negative sense 
luciferase reporter plasmid using 1µl per well of Lipofectamine-2000 (Invitrogen) in 
triplicate. The reporter plasmid was driven by a human, chicken or equine polymerase I 
promoter as required. As negative controls, the reporter was also transfected alone and 
alongside only three segments (PB1, PA, NP) to ensure activity was specific. After 24 
hours at 37 °C (293T) or 39 °C (DF-1) the cells were lysed with 250 µl Passive Lysis 
Buffer (Promega). 10 µl of lysate was mixed with 40 µl LARII luciferase substrate 
(Promega) and read immediately on a GloMax luminometer according to the 
manufacturer’s instructions. 
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4 Results 1: Characterisation of Infection Phenotypes in 
Equine Tracheal Explants.  
 
4.1 Introduction  
 
Avian influenza strains pose a significant threat to human and animal health if they 
are able to overcome the species barrier and become established in a novel host species. 
Recent years have seen repeated cases of human infections with avian H5N1 and H7N9 
influenza strain with high fatality rates6,101. These appear to be linked to many separate 
spill over events directly from birds, with little human-to-human transmission 56. No new 
human lineage has been established since the emergence of the swine-origin H1N1 virus in 
2009, although the morbidity of these infection events has been severe and the mortality 
rate high91,100. To infect and transmit efficiently, and be a genuine threat, the avian virus 
would have to become adapted to the novel human host.  
 
H3N8 EIV is an avian-origin virus that emerged in horses in the early 1960s110 and 
since then has been circulating continuously in equine populations despite the availability 
of vaccines. This is a useful model to study the establishment of an avian virus in a novel 
mammalian host and can be used to determine the requirements for mammalian adaptation. 
This is vital for surveillance of AIVs, which may pose a greater threat to human health. In 
order to determine whether EIVs have become more “equine-adapted” during more than 50 
years of circulating within the horse population, several aspects need to be considered. 
Different factors can contribute to virus adaptation to a new host species. For example, a 
well-adapted IAV would replicate efficiently and to high titre in the respiratory tract, be 
released from host cells and transmit easily between horses, before being neutralised by the 
host immune response.  
 
The first objective of this study was EIV evolution had a significant impact on the 
adaptation of the virus to the horse. Therefore, more recently isolated EIVs would have a 
different and more “equine adapted” phenotype of infection than the more distant “avian-
like” EIV isolates. The objective was to link genetic changes within the EIV lineage with a 
change in viral infection phenotype. To test this hypothesis, the phenotype of infection was 
determined for a panel of phylogenetically distinct EIVs in respiratory explants derived 
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from horse tracheas, as they would represent to a great extent the natural site of infection in 
the natural host.   
 
Infection phenotype was defined as a combination of growth kinetics and the effect 
of the viral infection on the histophysiology of the host tissue. Virus growth kinetics were 
to be measured by titration of viable virus from the tissue segment and 
immunohistochemical assay for the expression of viral antigen within the tissue. Damage 
to the host tissue was to be defined by histopathological examination of any lesions caused 
by the virus, a functional assay of cilia movement, and immunohistochemical assay for 
apoptotic markers. A trade off in terms of viral fitness between rapid viral growth and the 
destruction of the tissue was expected as total degradation of the tissue is not conducive to 
further virus growth.  
 
4.2 Virus Characterisation in vitro 
4.2.1 Phylogenetic Analysis 
 
To visualise the evolutionary relationship between EIVs and to select specific 
viruses for experimental testing, phylogenetic trees were inferred using EIV sequences 
generated in-house combined with 83 full genome sequences of EIVs available on 
GenBank. The separate avian-introduction Jilin/89 and an H3N8 avian-derived virus 
(AIV80) were included as outgroups to help define the lineage. The coding sequences of 
each segment were aligned in Mega 7 using Muscle Codon and phylogenetic trees were 
generated using the Neighbor-Joining method. This method was selected for its relaxed 
computing requirements and suitability for highly related sequences. A representative 
phylogenetic tree of HA is shown in Figure 4.1. 
 
The tree shows a clear separation between the outgroup viruses (AIV80 and 
Jilin/89) and the classical EIV lineage. This is consistent with Jilin/89 being the result of an 
independent cross-species transfer of AIV into horses as suggested by Webster118.  
 
Within the EIV lineage, this analysis shows a split between the very earliest 
isolates, 1963-72, and later isolates from 1976 onwards that has not been seen in other 
analyses such as Murcia et al (2011). Murcia et al conducted their analysis using a 
Maximum Likelihood approach, which is more robust to missing data, therefore the 
 Page 45 
 
paucity of samples from the earliest years of EIV circulation may make this portion of the 
tree the least reliable in the analysis. The rest of this analysis broadly agrees with that of 
Murcia et al., where the EIV lineage was classified into ten clades designated I-X, plus the 
well characterised Florida Clades 1 and 2, all of which are identifiable in the Neighbour-
Joining tree (Figure 4.1).  
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Figure 4.1: Neighbour-Joining (NJ) phylogenetic tree for the HA segment of EIV H3N8. Bootstrap values 
are shown next to the branches for (>70% of 1,000 replicates). Horizontal branches are drawn to a scale of 
nucleotide substitutions per site and Jilin/89 and AIV/80 were used as outgroups. Clades identified in Murcia et al 
2011 are highlighted with coloured boxes and numbered with roman numerals. Isolates selected for the study are 
highlighted with arrowheads.  
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4.2.2 Virus Selection 
 
In order to examine the evolution and adaptation of EIVs through time, a panel of 
viruses that would represent the evolutionary history of EIV were selected, including one 
virus per decade, with two sets of two from different countries but the same year as a 
control. These virus sets are highly genetically similar and so would be expected also to be 
similar phenotypically. Although A/Equine/Miami/63 is the most often cited early EIV 
isolate, it has been extensively passaged in the laboratory and is now a highly laboratory-
adapted virus and thus can no longer be considered representative, so Uruguay/63 was 
selected. Kentucky/95 could not be grown to the minimum required titre and so was not 
taken forward. As a control, an avian H3N8 isolate (A/Avian/Mongolia/80/2013) was also 
included in the panel.  
 
The viruses forming the panel to be studied represent five distinct clades of the 
lineage, clade I (Uruguay/63), clade III (Fontainebleau/79), clade V (Sussex/89), Florida 
Clade 1 (Ohio/03 and SouthAfrica/03) and Florida Clade 2 (Northamptonshire/13 and 
Mongolia/13).  Because of the evolutionary distances between the viruses selected 
different levels of adaptation were expected. 
 
The selected virus isolates were passaged three times in embryonated hens eggs to 
create a uniform background as previous passage history was unknown for several of the 
isolates and virus stocks were sequenced. Briefly, viral RNA was extracted, reverse 
transcribed and amplified. Library preparation for the Illumina MiSeq was performed by 
Dr Gaelle Gonzalez, sequencing by Dr Gavin Wilkie and consensus sequences generated 
by Henan Zhu. Consensus sequences were aligned to reference sequences obtained from 
GenBank, and where different, the sequence derived from in-house virus stock was used 
for analysis. In the case of AIV80, sequence data was provided with the virus by Connie 
Leung and Malik Peiris, University of Hong Kong. 
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Table 4.1: Virus isolates and characterization. PFU titre in pfu/ml.  
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4.2.3 Viral Stock Titres 
 
To fully characterise virus stocks, samples were assayed in triplicate for plaque 
forming unit (PFU) titre on MDCK cells and haemagglutination unit (HAU) titre using 
chicken red blood cells (cRBCs) (Table 4.1). The plaque assay tests the number of viral 
particles in a sample capable of infecting a cell and spreading to the surrounding cells. 
Haemagglutination tests the number of viral particles in the sample by agglutinating 
cRBCs together but gives no indication of virion infectivity. There was no clear correlation 
between PFU and HA titres, despite claims by some that one titre can be converted into 
another. Isolates with high PFU titres such as Sussex/89 (3e7 pfu/ml) and SouthAfrica/03 
(6e8 pfu/ml) did not have similar HAU titres (248 and 64 HAU respectively). Uruguay/63 
and Mongolia/13 have similar PFU titres (~6e5 pfu/ml) as do Fontainebleau/79 and 
Northamptonshire/13 (~3e4 pfu/ml) but their HA titres are very different in both cases. Nor 
does the PFU/HAU ratio show any distinct trend over time, although the avian virus 
AIV80 and the earliest EIV isolate had the two lowest HAU titres, irrespective of PFU 
titre. 
 
The variation in PFU/HAU ratio may have several possible explanations. The 
viruses with low PFU/HAU ratios may have poor fitness in the MDCK cells, so fewer 
particles are viable or able to form visible plaques. It is also possible that these viruses are 
producing large numbers of defective interfering particles (DIs) which have sufficient HA 
on the surface to agglutinate cRBCs but do not contain the full viral genome and are not 
viable to initiate infection in any cell line. qPCR to quantify the number of viral genomes 
present, or EM analysis to count particle numbers and normalisation to infectivity would 
be required to distinguish between these possibilities. As this investigation is primarily 
concerned with the infection capability of isolates, a PFU titre was used for the remainder 
of the experiments. Attempts to titrate by PFU on a potentially more relevant equine cell 
line were unsuccessful, and MDCK cells were used for titration. 
 
4.2.4 Plaque phenotypes 
 
To further characterise the selected viruses in vitro, the plaque phenotype of each 
virus was examined on MDCK cells. The plaque phenotype can be used in a limited 
fashion as a proxy of cell-to-cell spread. A larger plaque size means that more cells have 
been infected, suggesting efficient replication in the host cell and ease of exit and 
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reinfection under assay conditions. Plaque size may also relate to virus titre as more 
infected cells could be anticipated to result in more virus particles, all else being equal. The 
plaque assay was carried out in MDCK cells as a suitable mammalian-derived cell line, 
equine cell culture being unsuitable for plaque formation. Plaque size was measured after 
48 hours in 10 representative plaques in each experiment using the Image J software.  
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Figure 4.2: Plaque characterization of virus isolates. Immunostaining of plaque size at 48 hours. A) 
Uruguay/1963, B) Fontainebleau/1979, C) Sussex/1989, D)  SouthAfrica/2003, E) Ohio/2003, F) Mongolia/2013, G) 
Northamptonshire/2013, H) Avian80. I) Graphical representation of mean plaque size. Bars represent mean diameter 
and standard error of the mean (SEM) of 10 representative plaques from each of two independent experiments. 
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 Page 52 
 
The avian virus AIV80 and the earliest EIV isolate Uruguay/63 shared a large 
plaque phenotype on MDCK cells, although Uruguay/63 showed a distinctive clear area of 
dead cells or CPE (Figure 4.2A), which AIV80 did not (Figure 4.2H). The remainder of the 
EIVs showed a smaller plaque phenotype with or without CPE at the centre (Figure 4.2B-
G). Sussex/89 and Northamptonshire/13 in particular had very small pin-prick plaques, 
possibly indicative of a replicative incompetence (Figure 4.2C and G respectively). It is 
interesting to note however that Sussex/89 grew to high titre in embryonated chickens eggs 
(Table 4.1), so does not have a general replication defect. Titre in eggs is no predictor of 
plaque size as Sussex/89 and AIV80 shared similar stock titres, but very different plaque 
sizes. Unfortunately, no comparison of stocks grown in mammalian cell culture could be 
made.  
 
Contrary to expectations, large plaques were observed for avian and early equine 
isolates, not the more recent “equine-adapted” isolates. This suggests other factors in the 
size of plaques than merely replication efficiency.  
 
4.3 Ex vivo characterisation of EIVs. 
4.3.1 Explant Preparation  
 
The “ex vivo” tracheal explant system was developed as the most physiologically 
relevant system for viral infections short of live animal challenges, due to the logistical and 
ethical problems involved in such studies. The horses used in this study were two cull 
ponies from the semi-wild Dartmoor herd with severe cardiac defects. The Dartmoor herd 
are not vaccinated against EIV, and are immunologically naïve and therefore suited to our 
purpose. Immunological status was verified by HI. The ponies were humanely euthanised, 
and the trachea dissected out at post mortem. The tissue was immediately divided into 
three sections for ease of handling and transferred to pre-warmed media for washing. 
Preparation steps for the tracheal explants can be seen in Figure 3.1. Briefly, each tracheal 
section was divided in half lengthways, sectioned into rings and the epithelial tissue 
removed from the cartilage substructure. The explants were maintained at the air-liquid 
interface for up to 12 days, with media being changed every 5 days. 
4.3.2 Equine Tracheal Explants retain morphology for five days in culture. 
 
 Page 53 
 
The first objective of this study was to confirm that the equine tracheal explants 
retain all of the physiologically relevant features of the equine trachea in cultureTo monitor 
the viability of the explants in culture, explants were assessed every day for five days. 
Assessment included histological evaluation of morphological features and a bead 
clearance assay to determine ciliary activity. 
 
!
!
Figure 4.3: The equine tracheal explant retains normal morphology in culture for at least five days. A) H&E 
staining of tracheal explant after 5 days showing the epithelium (EP), Lamina Propria (LP) and Submucosa (SM) 
layers intact. Scale bar represents 250 µm. B) Close up of epithelium at day five showing retention of cell 
morphology. Scale bar represents 25 µm C) Time for bead clearance was unchanged across 5 days.   
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Equine tracheal explants were kept in culture and their morphology monitored for 
six days. The lamina propria and submucosa remain distinct at least six days post mortem 
(Figure 4.3 A), although without blood circulation the diffusion of oxygen and nutrients 
into the tissue becomes limiting. This may also influence the movement of virus particles 
within the tissue. There was no relaxation of the elastic fibres of the submucosa as 
described by Nunes123,124, suggesting better maintenance of the deep layers of the explant. 
At day five, all the constituent cell types of the tracheal epithelium were visible 
microscopically (Figure 4.3 B). Basal and goblet cells were identifiable and mucous was 
continuously produced, coating the surface of the explant and of the filter paper. The cilia 
that form a vital part of the mucociliary escalator are also evident as a pink fringe. The cilia 
continued to beat in a co-ordinated manner throughout the time course and beads were 
cleared from the apical surface in less than five minutes on all days tested (Figure 4.3 C). 
 
4.3.3 Viral Infection of Equine Tracheal Explants 
 
To determine a phenotype of infection, equine tracheal explants were infected with 
200 pfu of each of the selected viruses or mock infected. Samples were taken for virus 
quantification and histology, and the bead clearance assay performed every 24 hours for 
five days (See Figure 4.5), starting at 24 hours post infection (day 1). To titrate the virus 
present in explants, tracheal pieces were immersed in PBS, vortexed for 5 minutes, and 
plaque assays of the supernatant were used in standard plaque assays on MDCK cells (See 
Figure 4.4). Unfortunately, no results could be obtained following infection with 
Fontainebleau/79 due to microbial contamination. 
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Figure 4.4: Kinetics of virus growth for phylogenetically distinct EIVs in horse tracheas. Shown are means 
& SEM of two explants from each of two biological replicates 
  
 Page 56 
 
Each virus isolate tested exhibited a distinct kinetics of growth. All of the EIV 
isolates grew to a titre of at least 10e4 pfu/ml by day 2 post infection (pi), demonstrating 
their ability to replicate effectively in the equine respiratory tissue. Ohio/03 and Sussex/89 
displayed the biphasic virus growth kinetics previously seen in the infection of swine 
tracheal explants by Nunes et al123 and in vivo transmission studies in horses147. These 
viruses reached peaks of virus titre at day 2 and day 4 pi with a decrease in titre on day 3 pi 
in a manner which could not be explained by differences in biological replicates. The other 
EIVs displayed a single peak titre at day 2 pi, although the peak titre varied from 10e4 
pfu/ml for Sussex/89 to 10e8 pfu/ml for SouthAfrica/2003, although most isolates peak in 
the order of 10e6 pfu/ml. Year of isolation did not appear to correlate with peak virus titre.  
 
In contrast, the avian virus AIV80 did not produce measurable virus until day 3, 
peaking at day 4 pi. However, after this initial delay the peak titre was comparable to the 
bulk of the EIVs at 10e5 although there was some variation between repeats. This is 
similar to what was observed by Livia Patrono148. 
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Figure 4.5: Equine and Avian virus isolates display distinct phenotypes of infection in equine tracheal explants. 
Microbeads were applied to the explant and time for clearance estimated. Shown are means & SEM of two explants 
from each of two biological replicates. 
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Ciliary function is a measure of disruption of the epithelial physiology. As the virus 
replicates and is released from the host cell, the host cell dies, causing lesions to the 
epithelial surface. Two microlitres of a suspension of microbeads was applied to the apical 
surface of the tracheal explant and the time taken for clearance to one side of the explant 
was estimated. Increased time to clearance was an indication of cilia damage.  
 
The ciliary function assay had notable variation between the biological replicates, 
however all of the EIV isolates caused an increase in the time to bead clearance, suggesting 
damage to the beating cilia. For most this began at day 2 or 3 and progressed to complete 
or almost complete lack of ciliary function by day 5. Infection with SouthAfrica/03 was 
notable for the early onset of ciliary disruption and its severity. By day 3, bead clearance 
was almost totally abolished. In contrast, Sussex/89 only minorly affected bead clearance, 
with all explants managing to clear beads, and three out of four managing it in under five 
minutes on day five. Uruguay/63 was the most variable in its effect on bead clearance. On 
days 4 and 5, half of the explants could not clear the beads, while half did so in ten minutes 
or less. This is probably due to differences at the host level between the two biological 
replicates.  
 
Some correlation can be observed between the peak viral titre and the loss of ciliary 
function, e.g. SouthAfrica/03 had both the highest peak viral titre and very severe loss of 
bead clearance. Sussex/89 gave much lower peak viral titres and barely affected bead 
clearance at all. However, in the middle ground, the relationship seems more complicated. 
Northamptonshire/13 and Mongolia/13 had very similar viral titre kinetics, with a peak of 
the order 10e5. However, Mongolia/13 did not abrogate the ciliary function to the same 
extent as Northamptonshire/13.  
 
Again, AIV80 showed a very different phenotype in the ciliary function assay to 
the EIV isolates. Bead clearance was less than five minutes in all explants on all days, 
comparable to the uninfected explants. It is possible that due to the delay in replication 
indicated by the lack of detectable virus, the onset of cilia damage was missed in the 
window of the experiment and would have occurred later. It cannot be definitively said, as 
the uninfected explant would also degenerate over time. 
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4.3.4 Histopathological changes in infected equine tracheal explants. 
 
Each sample collected for histopathological analysis was fixed in formalin, before 
being sent for paraffin embedding and sectioning. For each sample, sections were taken for 
H&E staining (performed by the histology laboratory) and immunohistochemical staining 
with antibodies against the viral antigen NP and the apoptotic marker cleaved caspase 3. 
IHC slides were counterstained by the histology laboratory to reveal tissue morphology.  
 
As part of the characterisation of infection phenotypes, the level of lesions induced 
by the viruses at different time post-infection was determined. Typical influenza-induced 
lesions include the recruitment of eosinophils and apoptotic cells characterised by pyknotic 
nuclei, causing desquamation of the trachea and loss of cilia. To this end, H/E sections of 
infected and control explants were assessed using light microscopy. In addition, apoptosis 
was also evaluated by immunostaining of cleaved caspase-3.  
 
Each of the following figures comprises representative photographs for each 
condition at each time point, arranged by virus, and was used to define a histopathological 
phenotype of infection of the explants for each virus.  
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Figure 4.6 Equine Tracheal Explants retain morphology for 5 days in culture. Haematoxylin and Eosin 
(H&E) staining shows the morphology including ciliated cells are intact after 5 days. Infected cells were detected by 
immunohistochemical staining of the NP viral protein. Positive cells were stained brown. Apoptotic cells were 
detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. Scale bar represents 
25µm. Each panel is a representative image of two explants of each of two biological replicates 
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Figure 4.7: Infection of Equine Tracheal Explants with Uruguay/1963 displays an infection phenotype. 
Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. Infected cells 
were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained brown. 
Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. 
Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates. 
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Figure 4.8: Infection of Equine Tracheal Explants with Sussex/89 displays an infection phenotype. 
Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. Infected cells 
were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained brown. 
Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. 
Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates 
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Figure 4.9: Infection of Equine Tracheal Explants with SouthAfrica/03 displays an infection phenotype. 
Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. Infected cells 
were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained brown. 
Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. 
Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates 
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Figure 4.10: Infection of Equine Tracheal Explants with Ohio/03 displays an infection phenotype. 
Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. Infected cells 
were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained brown. 
Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. 
Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates 
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Figure 4.11: Infection of Equine Tracheal Explants with Mongolia/13 displays an infection phenotype. 
Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. Infected cells 
were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained brown. 
Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained brown. 
Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates 
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Figure 4.12: Infection of Equine Tracheal Explants with Northhamptonshire/13 displays an infection 
phenotype. Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. 
Infected cells were detected by immunohistochemical staining of the NP viral protein. Positive cells were stained 
brown. Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells were stained 
brown. Scale bar represents 25µm. Each panel is a representative image of two explants of each of two biological 
replicates 
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Figure 4.13: Infection of Equine Tracheal Explants with Northhamptonshire/13 displays an infection 
phenotype. Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells and damage. 
Infected cells were detected by immunohistochemical staining of the NP viral protein. Positive cells were 
stained brown. Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells 
were stained brown. Scale bar represents 25µm. Each panel is a representative image of two explants of each 
of two biological replicates 
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Mock-infected explants (Figure 4.6) were used as a control to assess the normal 
changes to the epithelium over the time course of the experiment. The H&E stained 
sections show the arrangement of the epithelial layer is constant throughout, with cilia 
present on all days with no major lesions within the epithelium, although a slight thinning 
of the depth of the epithelium reveals some loss of cells. This may be due to the loss of the 
circulatory system post mortem and the lack of available nutrients and oxygen. Some few 
cells stain positive (brown) for the apoptotic marker cleaved caspase 3, which would 
indicate a cell entering programmed cell death in response to damage and/or stress. Those 
visible on the first day were probably a reaction to tissue collection and processing. Cells 
can also be observed in an apoptotic state on days three and four, at the same time as the 
thinning of the epithelium, suggesting apoptosis is likely to be the mechanism of 
epithelium thinning. Uninfected tissue was also stained with an antibody to the viral 
antigen NP, to assess the possibility of prior infection or cross reactivity. No positively 
stained cells were observed in the controls on any day. 
 
Uruguay/63 is the earliest of the EIV isolates, representing the closest point of the 
lineage to the introduction into horses from birds, and was therefore hypothesized to be the 
least well adapted. It was predicted this would mean low efficiency replication and little 
damage to the tracheal structure due to the lack of virus activity. 
 
 However, infection with Uruguay/63 resulted in a higher level of tissue damage 
than expected (Figure 4.7). The epithelium lost much of its thickness along the course of 
infection. The layers became less regular, lost pseudostratification and defined layers, with 
evidence of vacuolation. In days 2 and 3 pi the cilia were highly damaged and by day 4 pi 
they were altogether absent, consistent with the loss of bead clearance at this time. The 
highest prevalence of caspase positive cells was also at this time as the epithelium thinned 
due to cells dying by apoptosis. The highest prevalence of NP positive cells was at day 2 
pi, indicating wide virus spread consistent with the peak of virus titre.  
 
 Infection with Sussex/89 showed very little damage to the epithelium (Figure 4.8). 
There was very little loss of depth even at day 5pi, and the cilia remained healthy 
throughout, comparable to the uninfected control. This explains the continued clearance of 
microbeads throughout the experiment seen in Figure 4.5. There was some evidence of 
vacuolation in the tissue, although of a limited extent. NP positive cells were few and 
found in discrete clumps unlike in the Uruguay/63 infected explants indicating little virus 
colonization of the tissue. This is likely to be related to the low viral titres found 
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throughout the time course. More caspase positive cells were seen on days 2 and 4, at the 
same times as peak viral titre, but cell apoptosis did not seem to have a perceptible effect 
on the depth of the epithelium. 
 
The histopathological phenotype of SouthAfrica/03 reflects the extremely high 
viral titre and especially the early abrogation of bead clearance previously noted (Figure 
4.9). Cilia damage at day 2 and destruction from day 3 pi were immediately obvious as was 
the disruption of internal epithelial morphology. From day 3 pi, vacuolation, loss of layers 
and recruitment of immune cells predominated. Many cells were stained positive for NP, 
particularly on day 3 pi as the virus overtook the entire tissue. This was the day after peak 
viral titre was observed, but the virus titre remained very high. Caspase activity was 
extensive throughout, indicative of widespread cell death. 
 
Although Ohio/03 was isolated in the same year as SouthAfrica/03, it presented a 
much less extreme phenotype (Figure 4.10). Damage to the cilia at the top of the 
epithelium did not become microscopically evident until day 3 pi, with some cilia still 
remaining on day 4 and (in patches) on day 5 pi. Thinning of the epithelial layer occurred 
at approximately the same time. There were extensive patches of debris no longer 
connected to the epithelium, presumably loosely attached dead cells that had been 
sloughed off into what would have been the lumen of the trachea. NP positive cells were 
seen from day 2 pi onward as the virus began to replicate, including day 3 pi despite the 
drop in virus titre observed. Caspase staining was highest on days 2 and 3 pi, the days with 
the most loss of epithelial thickness to apoptotic cell death.  
 
Mongolia/13 showed an interesting intermediate level of damage (Figure 4.11). 
Although the epithelium still retained much of its morphology and depth by day 5 pi, the 
cilia were damaged by day 3 and missing in patches from day 4 pi. The patchiness of cilia-
loss may explain the variability of the bead clearance in explants infected with this virus, 
as some explants retained clearing capacity, although it was slowed. The NP positive cells 
were also present in aggregates in samples infected with Mongolia/13, rather than 
dispersed throughout as seen with some of the other viruses. This suggested limited virus 
spread, although the titres observed do not indicate a lack of replicative efficiency. There 
were few cleaved caspase 3 positive cells, in agreement with the lack of epithelial thinning.  
 
Northamptonshire/13 had the more aggressive and damaging phenotype of the very 
recent EIV isolates (Figure 4.12). By day 3 pi there was a total loss of cilia, corresponding 
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to the loss of bead clearance at this time. The thinning and disruption of the epithelium was 
also more severe than that seen in infection with Mongolia/13. Many cells with pyknotic 
nuclei were observed from day 2 pi (indicated by arrows). As with SouthAfrica/03, the 
highest numbers of NP positive cells were observed on day 3 pi, the day after peak viral 
titres but the distribution was more similar to the clumps seen with Mongolia/13. Peak 
caspase activity was observed at day 2 pi, at the time of maximum destruction, consistent 
with apoptosis-mediated damage.  
 
The avian virus AIV80 had a histopathological phenotype of infection completely 
different from all the EIV isolates except Sussex/89 (Figure 4.13). Almost no damage was 
visible at all across the time course of infection. The epithelium did not become thinner or 
more disrupted. No vacuolation or recruitment of inflammatory cells was observed. The 
cilia remain healthy, in accord with the perfect bead clearances throughout. Interestingly, 
very few NP positive cells could be detected even on days 4 and 5pi, when viral titres were 
comparable to those of the EIV infected explants. Caspase positive cells were observed 
only on days 1 and 2 pi, before detectable virus release and at a similar time and level to 
the uninfected control. Apoptosis of these cells was most likely a response to post mortem 
sectioning. 
 
In order to make comparisons between early and late EIV isolates, two summary 
figures are provided, one at day 2 (Figure 4.14) and the other at day 5 pi (Figure 4.15). 
Here the focus is on one early date “avian-like” EIV isolate (Uruguay/63) and one recent 
date “equine-like” EIV (Ohio/03) with the avian AIV80 and uninfected explants as 
controls. Ohio/03 was selected for the prototype of an “equine-adapted” virus as it is the 
best characterised since it is from the time of CIV emergence.  
 
  
 Page 71 
 
Figure 4.14: Summary of histological phenotypes of infection of Uruguay/63, Ohio/03 and AIV day 2 pi 
relative to mock infected. Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells 
and damage. Infected cells were detected by immunohistochemical staining of the NP viral protein. Positive cells 
were stained brown. Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells 
were stained brown. Scale bar represents 25µm. Each panel is a representative image of two explants of each of 
two biological replicates. 
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Figure 4.15: Summary of histological phenotypes of infection of Uruguay/63, Ohio/03 and AIV day 2 pi 
relative to mock infected. Haematoxylin and Eosin (H&E) staining shows the morphology including ciliated cells 
and damage. Infected cells were detected by immunohistochemical staining of the NP viral protein. Positive cells 
were stained brown. Apoptotic cells were detected by immunohistochemical staining of caspase-3. Positive cells 
were stained brown. Scale bar represents 25µm. Each panel is a representative image of two explants of each of 
two biological replicates. 
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At day 2 pi, the tissue infected with Uruguay/63 was highly disrupted while that 
infected with Ohio/03 was less so. Both contain many NP positive cells, indicating 
widespread virus colonization of the tissue. The Ohio/03 infected explant had more 
identifiable caspase positive cells, which are an indication of imminent cell death and the 
damage yet to come. The explant infected with AIV80 was undamaged, no viral antigen or 
apoptotic cells were detected, and it remained histologically similar to the mock-infected 
explant. 
 
At day 5, the explants infected with either EIV isolate were highly damaged: no 
cilia remained, the integrity of the epithelium was compromised and it was visibly thinned. 
Due to the extent of the cell loss, there were few cells positive for virus antigen or caspase 
3. The explant infected with AIV80 still remained undamaged, epithelium and cilia intact 
as in the uninfected explant. Very few cells stained positive for NP, raising the question of 
whether virus spread was so limited as to be almost undetectable despite measurable titre 
in the supernatant. Caspase staining was also very limited, although this was consistent 
with the health of the epithelium and apoptotic cells would not be expected. A further 
summary comparing tissue damage as seen by H&E staining with virus kinetics is 
displayed in Figure 4.16. 
  
 Page 74 
 
  
Figure 4.16: Summary of infection phenotypes of infection of Uruguay/63, Ohio/03 and AIV day 
2 pi relative to mock infected. Including cilia function virus kinetics and Haematoxylin and Eosin (H&E) 
staining. Scale bar represents 25µm. All figures are as detailed above. 
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4.4 Discussion 
 
In this chapter, a phenotype of infection for a panel of phylogenetically distinct EIV 
isolates was determined in order to determine their degree of fitness in the equine trachea. 
The hypothesis was that isolates with a later date of isolation would be fitter in the horse 
tracheal explants than those of an earlier date as the late virus would have had a chance to 
become well adapted as they had circulated in horses. The earlier isolates were predicted to 
be more “avian-like” and comparable to the avian virus control. 
 
Each EIV isolate has a distinct phenotype of infection in both in vitro and ex vivo 
experimental systems. The correlation between the two is very weak. Assays such as 
PFU/HAU ratio and plaque size may give an idea of virus infectivity and cell-to-cell 
spread in vitro but do not seem to indicate efficient replication or a highly destructive 
phenotype of infection in the equine tracheal explant system. SouthAfrica/03 had both high 
peak titre and very destructive histopathology, with a small plaque phenotype. Sussex/89 
grew to high titres in eggs, and had very small plaques but did not replicate to high titres in 
the explants, nor did it produce much damage. Efficient replication and cell-to-cell spread 
in vitro do not translate to the ex vivo system. Possibly the more recent isolates kill the 
cells too quickly for efficient spread and large plaque formation. Possibly the MDCK 
system is a poor model, either because it is canine derived, or because it is interferon 
incompetent149,150. MDCK cells are noted for being highly permissive to infection by many 
strains of IAV, including avian-derived strains. 
 
Two distinct patterns of EIV replication in the ex vivo system were observed. The 
majority of the isolates showed a monophasic growth, with a single peak in virus titre 
achieved at day 2, although this peak titre ranged from 10e5 to 10e8 pfu/ml in a manner 
not correlated with date of isolation. Two virus isolates, Sussex/89 and Ohio/03 had a 
second peak of virus titre on day 4, more similar to what had previously been observed in 
swine tracheal explants. This was the only feature of their infection phenotype shared by 
the two isolates however.  
 
There was also a wide variation in the damage caused by each virus isolate, again 
not well correlated with the phylogenetic position in the EIV lineage. There was some 
indication that high virus titres were accompanied by destruction of the epithelium, 
although this was not consistent in every case. Mongolia/13 was a notable exception with 
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high level virus replication, but limited damage beyond the cilia of the epithelium. The 
severity of the outbreak from which each virus was isolated was not consistent with the 
destructive potential of the virus. There seems to be a trade-off to get high titres quickly or 
a sustained lower level of virus replication without totally incapacitating the host. A semi-
quantative scoring system for epithelial damage was envisioned to allow direct comparison 
between explants. However, the minimum number of biological replicates to set up such a 
system was ten horses, well beyond the scope of this study. 
 
The severity of epithelial damage ex vivo does not seem closely correlated with the 
clinical presentation of disease caused by each isolate. SouthAfrica/03 has long been 
known as a highly virulent strain, causing high morbidity in the infected animals (John 
Marshall, personal communication), compared to other strains of a similar time. This is 
borne out in the high degree of tracheal damage compared to that caused by Ohio/03. 
However, Sussex/89 also caused a very grave outbreak. This indicates that there are many 
factors dictating the severity of an outbreak beyond the virus characteristics, including the 
preponderance of naïve hosts either due to the introduction of EIV to a new country, as in 
South Africa in 2003 or due to vaccine escape as in England in 1989.  
 
One of the most salient features of this investigation is that the oldest EIV isolate in 
the panel, Uruguay/63, was able to efficiently infect the equine tracheal explants and 
replicate to good titre. In fact its phenotype of infection is much more similar to the 
majority of EIV isolates than to the avian isolate, contrary to the prediction that it would 
have a less well adapted phenotype. This raises several interesting questions. The famous 
Red Queen Hypothesis, that it “takes all the running one can do, just to stay still” suggests 
that a virus can co-evolve with its host defences without gaining any measurable 
advantage. However, there are simpler explanations. Back calculations of the rate of EIV 
sequence divergence from AIV isolates suggest that H3N8 influenza has been infecting 
horses since at least 1950110 but was not identified until 1963. It is possible that in the 
interim the virus has become sufficiently equine-adapted to be comparable to the other EIV 
isolates. Alternatively, outbreaks of H3N8 EIV on a noticeable scale may not have been 
possible until the virus had become sufficiently well adapted to replicate well in the equine 
trachea. This system also does not test the ability of Uruguay/63 to evade the host adaptive 
immune system or transmit between horses. These are crucial elements of viral fitness that 
must be gained to be a “well-adapted” virus to a novel host. 
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In vitro, the earliest EIV isolate Uruguay/63 behaved more like the avian isolate 
AIV80 than the other EIV isolates, with a high PFU/HAU ratio and large plaque 
phenotype. However, in the tracheal explant system, the avian virus has a totally distinct 
phenotype of infection. Replication is delayed by at least three days compared to the 
equine-derived isolates. This is presumably due to some barrier to replication in the equine 
cells that the avian virus is slow to overcome. It also does not cause damage to the tissue 
structures within the time frame of this experiment. It would be interesting to see whether 
this would occur on a delayed time scale similar to the delay in replication, although it has 
not been possible to test this idea in this instance.  
 
The phenotypes of infection of the equine tracheal explant by so many virus 
isolates are very difficult to interpret, due to the large degree of variability between the 
hosts. Although, ex vivo explant systems are the closest system to living horses available in 
a laboratory setting, their use does have some drawbacks. It is not possible to calculate 
exact MOIs as the exact cell number of the tissue section cannot be determined without 
tissue destruction. Sections were cut to a standard size to give an approximately equal cell 
number. The cell population may also vary between explants, so mixtures of explants from 
different regions of the trachea were used for replicates in order to ensure a representative 
sample.  
 
Chambers et al126 have suggested that the lack of adaptive immunity makes the 
tracheal explant system a poor model of viral fitness in the host. In their experiments, 
viruses able to replicate in the tracheal explant system were not found to infect horses 
efficiently or to transmit between horses. The system also lacks a marker for ease of 
transmission between individuals. However, as a system to examine the efficiency of virus 
replication in a physiological set up, distinct from transmission and immune evasion, the 
tracheal explant system is unsurpassed. Ex vivo cultures are becoming increasingly 
accepted in “reducing, replacing and refining” animal models of infectious disease.  
 
Other limitations of this study include the titration of inoculum virus in MDCK 
cells that was done for ease of comparison across stock levels. If different isolates have 
different levels of infectivity in tracheal cells, the effective titres in tracheas might be 
different and any differences detected are simply due to a higher or lower effective dose in 
the inoculum. qPCR titration by genome copy number was considered, after HAI titre was 
shown to be irreproducible with different aliquots of chicken red blood cells. However, as 
the isolates were already shown to have widely varying particle: infectivity ratios, the 
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decision to use a titre based on infectivity was made to try to have as comparable starting 
conditions as possible for infection-based assays.  
 
Despite these limitations, the ex vivo system gave an interesting insight into the 
panel of phylogenetically distinct EIVs. Two distinct kinetics of infection, mono- and bi-
phasic, were observed, alongside differences in tissue damage and clearance. The EIV has 
clearly changed in more than one respect since the initial isolation. In order to investigate 
these differences further, a more molecular approach was decided upon.  
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5 Results Chapter 2: Replication kinetics of 
evolutionarily distinct EIVs in vitro 
 
5.1 Introduction  
 
In the process of adapting to a novel host, IAVs acquire mutations that allow them 
to replicate and transmit more efficiently in the new host species. Examination of these 
mutations can shed insight on the workings of influenza and the molecular barriers to 
infection of a new species or group of species. Molecular determinants of adaptation can 
be found in any, or all, of the eight IAV segments151,152. Mutations in HA or NA may 
influence the ability of the virus to enter or exit host cells, distinct from antigenic drift to 
avoid neutralising antibodies. Changes in the polymerase may be necessary for efficient 
production of viral proteins or viral RNA in a novel host, including recruitment of required 
host factors. Evasion of the novel host immune system is also a major driver of change, 
especially in the NS segment. 
 
In vitro studies are suitable to examine the evolution and adaptation of EIV at the 
molecular level because they allow much greater control over several aspects of viral 
infections, such as an accurate multiplicity of infection and better standardisation between 
assays without the variability between animals observed with in vivo and ex vivo systems. 
Reverse genetic technology is a unique asset to examine the relative contribution of 
individual genomic segments to EIV adaptation. This technology allows genetic 
manipulation of viruses as both segment-reassorted and specific site mutants can be 
generated from plasmids and their effects on the viral phenotype assessed.  
 
5.1.1 Aims  
 
The aim of this section of the study was to uncover which virus segment or 
segments were responsible for the differences in infection phenotype between a more 
distant “avian-like” EIV, Uruguay/63 and more recent “equine-adapted” Ohio/03 and 
examine mutations that might be responsible for this adaptation. To this end, the objective 
was to develop reverse genetic plasmid sets for both older and recent EIVs and use these to 
determine their phenotype of infection in different cell lines in vitro. The dual-sense 
plasmid set comprising the reverse genetic rescue system for Ohio/03 was kindly provided 
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by Daniel Perez (University of Georgia), and the other reverse genetic viruses were 
developed based on this set. To test the fitness of viruses within different cellular contexts, 
experimental infections in equine and avian cell lines were performed. These would then 
be used to create reassortant viruses generated by reverse genetic virus rescues to examine 
which virus segments were responsible for differences in replication phenotype.  
 
5.2 Reverse Genetic Virus Generation 
5.2.1 Virus cloning  
 
Several viruses of interest were selected from previous experiments for the 
generation of reverse genetic virus plasmid sets. Specifically, the interest was in analysing 
the differences between the most “avian-like” EIV isolate, Uruguay/63, and a newer, more 
“equine adapted” EIV such as Ohio/03, which is well characterised. Fontainebleau/79 was 
selected as an intermediate point between these two. Additionally, AIV80 was selected as 
an avian virus control, and Jilin/89 as a separate “avian-like” EIV from a distinct host-
jump event. A plasmid set for the Ohio/03 virus was already available125. All other viruses 
or individual genomic segments were cloned into the same dual sense virus rescue vector 
pDP2002. 
 
Briefly, RNA was extracted from a sample of each virus (except Jilin/89, for which 
RNA had been provided by Robert Webster (St Jude Children’s Research Hospital, 
Memphis)), reverse transcribed and amplified using the universal primer sets 12 and 12G 
described in Zhou et al141 to amplify all segments. The 12G primer set is optimised to 
amplify the larger polymerase segments PB1, PB2 and PA, while the primer set 12 is 
suitable to amplify all other segments. These were then used as templates in the secondary 
PCR, using the segment specific primers developed by Hoffman et al145, which bind to the 
UTR of each viral segment. Figure 5.1 shows an example of a gel with all the genome 
segments amplified.  
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Figure 5.1: Full genome amplification of equine influenza viruses. A) Whole genome amplification of 
Fontainebleau/1979 using the 12G and 12 primer sets. B) Segment- specific amplification using primers as 
described in Hoffmann et al145. Asterisks indicate bands purified for plasmid generation.  
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Due to the conserved nature of UTRs, minor bands can be seen in some reactions 
with especially high cross-binding of the primers to HA and NS. The correct product was 
selected on the basis of molecular weight by agarose gel electrophoresis (highlighted in 
figure 5.1) and gel purified. The segment specific primers included a recognition site for 
the restriction enzyme BsmBI to facilitate cloning into the pDP2002 vector. BsmBI was 
chosen because it cuts the DNA nine nucleotides downstream of its recognition site and 
therefore leaves no “cloning scar” in the resulting plasmid. The viral segment, including 
UTRs, could be positioned directly at the transcriptional start site of the RNA polymerase I 
promoter without the addition of any bases. The UTR therefore is still able to act as the 
viral promoter and bind the viral polymerase. 
 
 The RT-PCR approach was not always successful. The polymerase segments 
(PB1, PB2 and PA) were the most difficult to insert into the vector backbone likely due to 
the nature of their large size. For example, during the cloning of the AIV80 polymerase 
segments, large deletions were repeatedly observed within the coding region upon 
sequencing of various clones. For Jilin/89, it was not possible to amplify the full genomic 
segments, likely due to the low integrity of the initial RNA extract. For this reason, some 
genomic segments were chemically synthesised. This method has gained popularity in 
recent years, especially for the creation of new vaccine strains because of the fast 
turnaround time153,154. The Jilin/89 consensus sequences, and the PB2, PB1 and PA 
segments of AIV80 were synthesized by GenScript and cloned into the dual sense 
backbone pDP2002 as described above. Table 5.1 shows the viruses cloned and how each 
genomic segment was obtained.  
 
Virus PB2 PB1 PA HA NP NA M NS 
Uruguay/63 RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR 
Fontain
ebleau/79 
RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR RT-PCR 
Jilin/89 Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
AIV80 Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
Gene 
synthesis 
RT-PCR RT-PCR RT-PCR RT-PCR 
 
Table 5.1: Summary of reverse genetic virus segment origins. 
 
 Page 83 
 
All plasmids were sequenced, and the viral sequence shown to be identical to the 
reference sequence for each virus. Where the original isolate had been sequenced in house, 
the in house consensus sequence was used as a reference.  
 
5.2.2 Rescue and Validation of Reverse Genetic Viruses.  
 
Co-cultures of 293T and MDCK cells were transfected with the plasmids described 
above to rescue the viruses. As the work was carried out under BSL2 conditions, and given 
the known high pathogenicity of Jilin/89 in horses -as well as its absence in the UK- 
attempts to rescue this virus were not performed.  
 
Uruguay/63 and Ohio/03 were successfully rescued but not Fontainebleau/79. Upon 
rescue, viruses were grown in in two passages on MDCK cells, RNA-extracted and 
sequenced. The consensus sequences of the reverse genetic viruses were identical to those 
of the parental stocks. For more accurate comparison with the original isolate viruses, the 
isolate strains were also passaged twice in MDCK cell culture.  
 
To compare the biological properties between the rescued viruses and the isolates, 
MDCK cells were infected with each virus. Growth kinetics of the viruses were compared 
by titre of the supernatant, as well as the size and shape of the virus plaques (Figure 5.2). 
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Figure 5.2: Plaque size and growth kinetics of reverse genetic rescued viruses are comparable to those of 
natural isolates. Immunostaining of plaque size at 48 hours: A) Uruguay/1963 isolate (i), B) Uruguay/1963 reverse 
genetic (rg), C) Ohio/2003 isolate (i) D) Ohio/2003 reverse genetic (rg). E) Mean plaque size of ten plaques in each of 
two independent repeats. Error bars indicated SEM. F) Growth kinetics of viruses on MDCK cells, error bars 
indicate mean and SEM of two independent experiments in triplicate.  
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As shown previously in Figure 4.2, Uruguay/63 isolate (Uruguay/63i) has a larger 
plaque size than the Ohio/03 isolate (Ohio/03i), with occasional clear centres of CPE, 
which the later isolate does not display. The Uruguay/63 reverse genetic virus 
(Uruguay/63rg) has a large plaque phenotype similar to the corresponding isolate, however 
the clear CPE centre is less common with the reverse genetic virus. The Ohio/03 reverse 
genetic virus (Ohio/03rg) shares a small plaque phenotype with Ohio/03i. Although the 
average plaque size appears slightly larger, this is not significant by unpaired t-test with 
Welch correction (p=0.1). Based on these results, the plaque morphologies of the reverse 
genetic rescued viruses were comparable to that of the isolates they were derived from.  
 
The replication kinetics of the viruses in MDCK cells were next tested. Ohio/03i 
grows rapidly in this cell line, reaching a peak of 1e9 pfu/ml by 24 hours post infection 
(hpi) and maintaining this level through the rest of the time course. Ohio/03rg showed 
similar kinetics of replication, with a slightly higher peak titre (Figure 5.2F). Uruguay/63i 
displayed slower growth kinetics, appearing to reach its peak at 48 hpi. This peak titre was 
also lower than that of the Ohio/03i, at approximately 1e8 pfu/ml. The reverse genetic 
virus attained a similar peak titre, although this seemed to be reached at the earlier time 
point. Overall, the growth kinetics of each pair of viruses were very similar and the virus 
isolates and reverse genetic viruses were considered to be comparable. For this reason, 
reverse genetic viruses were used in downstream experiments.  
 
5.3  Comparison of Growth Kinetics in vitro. 
5.3.1 Wild type viruses 
 
In order to assess the degree of virus adaptation to a mammalian cell system, the 
viruses were used to infect cell lines of different origin species to compare their fitness in 
each. The E derm cell was expected to support efficient replication of equine-adapted 
viruses due to its equine origin. Although E derms are a dermal fibroblast derived cell line, 
and influenza viruses normally infect epithelial cells, EIV infection of E derm cells has 
previously been reported155. Attempts to create or source more physiologically relevant 
equine cell lines were unsuccessful. Other equine fibroblast cell lines, such as papilloma 
transformed SO4 and S62 cells were too slow-growing for practical application. Equine 
oviductal epithelial cells were kindly provided by Barry Ball at the University of 
Kentucky, but were not viable due to very long term freezing (20 years) and poor shipping 
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conditions. Primary cells isolated from respiratory epithelium were resistant to 
immortalisation by transfection or lentivirus infectionto create a cell line and numbers were 
too low for infection of pure primary cultures.  
 
The chicken fibroblast cell line DF-1 is known to support the replication of 
AIVs156–158, and was predicted that the older and more “avian-like” EIV virus, would be 
better able to infect and replicate in these cells.  MDCK cells are a non-equine mammalian 
cell line known to be highly permissive to infection by many influenza strains 150,159 and 
would represent a “level playing field” on which virus strains could be easily compared. 
 
To determine the efficiency of infection and replication of the viruses in the 
different cell monolayers, the cells were infected with the viruses (MOI=0.1) and used the 
supernatant to determine the virus titre and the cells to determine the proportion of infected 
cells by FACS. A time point at six hours post infection was collected as a baseline, as it 
was considered to be during the “eclipse phase” of viral replication and before the release 
of progeny virions. This allowed me to measure both the capability of the viruses to infect 
each cell type and the efficiency of replication in infected cells. The AIV80 isolate was 
also included as a control.  
  
 Page 87 
 
 
 
Figure 5.3: Infection kinetics of Uruguay/63, Ohio/03 and AIV80 in cells of different animal origin. Wild-
type viruses have differing replication competencies in cell lines of different species origins. Virus growth kinetics 
in A) MDCK B) DF-1 and C) E derm. Cells were infected with an MOI of 0.1, stained for NP viral antigen and 
quantified by FACS for D) MDCK, E) DF-1 and F) E derm cells. Error bars indicate mean and SEM of three 
independent experiments in triplicate. 
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As observed in Figure 5.3A, both EIVs readily grew to a high titre in MDCKs at 24 
hpi and maintained this titre up to the final time point at 72 hpi. Ohio/03 had a peak viral 
titre approximately one log higher than that of Uruguay/63 at 1e9 and 1e8 pfu/ml 
respectively. In contrast, AIV80 had a slower growth kinetics, and a lower peak titre of 
approximately 1e7 pfu/ml at 48 hpi. By FACS analysis (Figure 5.3D), the percentage of 
positive cells increased steadily across the time course of infection, although at every point 
Uruguay/63 had more infected cells than Ohio/03. This may be because the cells infected 
with Ohio/03 died at earlier time points and in greater numbers than those infected with 
Uruguay/63 (data not shown). AIV80 infection showed a much lower number of infected 
cells, about 10% at most time points, although this seemed to increase slightly at the final 
time point. This slow replication of the avian virus and poor expression of virus antigen are 
reminiscent of the replication phenotype in tracheal explants.  
 
Upon infection of the avian-origin DF1 cell line (Figure 5.3B), AIV80 was able to 
grow at higher titres than the two EIVs, as expected. Virus titre continued to rise until the 
final day with a maximum titre of 1e6 pfu/ml. Both EIVs showed very similar kinetics, as 
they increased in titre in the first 24 hours, to a peak of 5e4 pfu/ml, but were not able to 
maintain titre in the same way as the avian virus. Uruguay/63, the more “avian-like” of the 
two perhaps maintained titre slightly better than Ohio/2003 but this was not significant. By 
FACS analysis (Figure 5.3E), very few cells were expressing virus antigen regardless of 
which virus they had been infected with. AIV80 was able to infect nearly 10% of cells at 
24 hours whereas the EIV infected cells were not significantly above background at any 
time point. This is consistent with the cytopathic effect observed in cells infected with the 
avian, but not the equine derived viruses.  
 
In the equine-origin E derm cell line (Figure 5.3C), the equine-adapted EIV 
Ohio/03 reached a peak titre of 1e6 pfu/ml by 48 hours post infection. At this time point, 
the monolayer was almost completely destroyed, similar to the destruction seen in the 
infection of the equine tracheal explants. This is reflected in the drop in the percentage of 
cells positive for virus antigen by FACS analysis (Figure 5.3F). EIV Uruguay/63 reached 
its peak at 24 hpi (5e4 pfu/ml). Interestingly, the virus growth until this timepoint 
paralleled that of Ohio/03. In contrast, a smaller proportion of cells were killed by 
Uruguay/63 than by Ohio/03, and more cells (up to 30%) were infected by the former 
based on FACS analysis. AIV80 showed no measurable increase in titre until the final time 
point, which was very slightly elevated, although the percentage of NP positive cells 
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increased steadily to 25% by 72 hours post infection. AIV80 is clearly able enter the cells 
and replicate to some degree, but not to spread efficiently. 
 
Both EIVs out-replicated the avian virus AIV80 on both mammalian derived cell 
types as expected, growing to significantly higher titres. In avian cells the opposite was the 
case as the avian virus AIV80 was able to replicate better than the two EIV strains, which 
were at a similar replicative disadvantage. In both equine and canine cells, the more recent 
Ohio/03 was able to replicate to a peak titre at least one log higher than that of the more 
distant Uruguay/63, suggesting that it was better adapted to replicate in a mammalian in 
vitro system. Ohio/03 infects a lower number of cells but produced more virus than 
Uruguay/63, which may suggest more efficient replication. However, the FACS data 
suggested that there was no difficulty for Uruguay/63 to enter either the MDCK or E derm 
cells. This suggested that the mechanism of adaptation was unlikely to be found in the 
external viral proteins HA and NA and was rather due to differences in the internal 
genomic segments.  
 
5.3.2 Polymerase swapped viruses 
 
As differences were in the likely replication ability of EIVs that were not due to the 
ability to enter equine cells, the decision was made to look for viral determinants of 
mammalian adaptation in internal genomic segments. This search focused on the 
polymerase genes, as they are directly responsible for the synthesis of nucleic acids and 
genome replication. In order to further investigate which of the internal genes were 
responsible for the different phenotypes, reassortant viruses were generated with swapped 
polymerase segments. The Uruguay/63 backbone (HA, NA, M, and NS) with the Ohio/03 
polymerase segments (PB2, PB1, PA, and NP) was termed U/63Ohpol. The reverse swap of 
the Ohio/03 backbone (HA, NA, M, and NS) with the Uruguay/63 polymerase segments 
(PB2, PB1, PA, and NP) was termed O/03Upol. Virus genomic structures are displayed in 
Figure 5.4.  
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Figure 5.4: Reassortant Virus Composition. Segments from Uruguay/63 (Green) and Ohio/03 (Blue) were 
combined to create reassortant viruses with the external genes of Uruguay/63 and polymerase complex of Ohio 
(U/63Ohpol) or the external genes of Ohio/03 and the internal genes of Uruguay/63 (O/03Upol). 
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These viruses were rescued, grown up in MDCK cells and used to infect MDCK, 
DF-1, and E derm cells as previously described. The hypothesis was that U/63Ohpol would 
have a replicative advantage over Uruguay/63 in mammalian cells, and be disadvantaged 
in the avian cell system. Conversely, O/03Upol was expected to be less efficient in 
mammalian cell infection than the Ohio/03 parental virus. 
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Figure 5.5: Polymerase-swapped viruses display intermediate phenotypes to wild-type parent viruses. 
Virus growth kinetics in A) MDCK (canine widely permissive cell line) B) F-1 (chicken cell line) and C) DE derm 
(equine cell line). Trypsinised cells were stained for NP viral antigen and quantified by FACS for D) MDCK, E) DF-1 
and F) E derm cells. Error bars indicate mean and SEM of three independent experiments in triplicate. 
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In MDCK cells, the addition of the Ohio/03 polymerase into the Uruguay/63 
backbone allowed U/63Ohpol to grow to a titre comparable to the Ohio/03 wild type virus at 
approximately 1e9 pfu/ml, and higher than the Uruguay/63 wild type virus. U/63Ohpol virus 
killed less of the monolayer than the Ohio/03 virus and this may be reflected in the high 
percentage of cells expressing NP seen at each time point. The other polymerase swap 
virus, O/03Upol, also exhibited intermediate kinetics between the two parental viruses. The 
peak titre was about 5e8 pfu/ml, between that of the wild type viruses. It destroyed the 
monolayer in a manner similar to infection with the Ohio/03 wild type virus, and had very 
similar proportion of infected cells by FACS analysis.  
 
In DF-1 infection, U/63Ohpol grew to markedly lower levels than Uruguay/63 by 48 
hpi (Figure 5.5). Instead of the Uruguay/63 peak at 5e4pfu/ml, the U/63Ohpol virus only 
managed to grown one log above its starting point, to 5e3, and returned to inoculum levels 
by 48 hours. The virus titre was more than one log below the Uruguay/63 wild type virus at 
every time point after the initial 6 hour baseline, and also significantly lower than the 
Ohio/03 parental virus. In turn, Oh/03U63pol grew to significantly higher levels than 
Ohio/03, comparable to that of the Uruguay/63. This seems to indicate that the polymerase 
complex of Uruguay/63 enhances replication in avian cells. The polymerase origin seems 
highly deterministic of fitness in the DF-1 infection system. 
 
On infection of E derm cells, both reassortant viruses had kinetics of infection more 
similar to the Uruguay/63 parental virus than the Ohio/03 virus, peaking at 24 hours post 
infection and then dropping off. The peak titre was half of a log higher than that of 
Uruguay/63 in both cases, however it was not comparable to the titre achieved by Ohio/03. 
U/63Ohpol pol had the faster decrease in titre and was comparable to the Uruguay/63 wild 
type at 48 and 72 hours post infection. The greatest difference between the two reassortant 
viruses is in the FACS analysis. Although Oh/03U63pol was able to express antigen in a 
proportion of cells similar to the Ohio/03 virus, the U/63Ohpol NP was only detected in a 
minority of cells. It was unclear whether this was due to a difference in cell entry or in the 
differences in cell death caused by the two reassortant viruses. In mammalian cell 
infections, the polymerase swaps appeared to have intermediate phenotypes of infection 
between the two parental viruses, and the origin of the polymerase made a quantitative 
rather than qualitative difference to replication kinetics. Ohio/03 is the fittest in 
mammalian cells, while U/63OhPol replicates slightly better than Uruguay/63 despite the fact 
that infects many fewer cells, though this may be due to cell death. 
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5.4 Discussion 
 
In this chapter, reverse genetic plasmid systems for phylogenetically distinct EIV 
isolates were generated and it was demonstrated that the rescued virus had properties 
comparable to the naturally isolated and passaged virus in cell culture. They have the same 
consensus sequence, although it is assumed that the rescue has a less dispersed viral 
cloud160. The plaque phenotypes and kinetics of replication on MDCK cells are also 
comparable. These reverse genetic plasmid sets are a very useful tool for manipulating 
viruses to better understand them. Both wild type rescued virus and the reassortant progeny 
that can be created allow us to pick apart the effects of a single gene or gene clusters on 
viral phenotypes of infection. However, this is not a perfect system. There appear to be 
limitations that are not fully understood in which combinations of segments are viable for 
rescue to produce infectious virus. It is also possible that, deprived of the cloud of viral 
variations described by Domingo et al160 the reverse genetic virus will lose some fitness or 
otherwise alter in character compared to the isolate virus.  
 
Using reverse-genetics generated viruses to infect cells in vitro, the more recent 
EIV Ohio/03 appears to have a replication advantage in the mammalian-derived cell lines 
over the older more “avian-like” Uruguay/63. Both in the equine cell line (E derm) and the 
highly permissive MDCKs, Ohio/03 grew rapidly to a higher titre than Uruguay/63. 
Uruguay/63 was able to infect and replicate robustly in both cell lines, despite achieving 
lower peak titres than Ohio/03. Infection with Uruguay/63 resulted in higher proportions of 
cells expressing the NP antigen than Ohio/03, in part due to the less destructive effect 
Uruguay/63 had on the monolayer. It seems logical that Uruguay/63 is able to replicate 
efficiently in mammalian-derived cells, as it was fully capable of achieving in vivo 
infections and horse-to-horse transmissions during the equine influenza outbreak from 
which it was isolated. No statistical analysis was performed on these growth curves, on the 
advice of Seem Nickbash, University of Glasgow statistician, as the large number of 
confounding variables increased the expectation of false-positives above an acceptable 
threshold. Patterns of replication kinetics were therefore compared in a qualitative manner. 
 
The avian-derived control AIV80 was much less able to replicate in the mammalian 
derived cell lines than the EIVS. In MDCKs it grew slowly to a lower peak titre, while in E 
derm infections no virus was measureable until the final day. It is possible that this 
represented a delay in replication similar to that seen in AIV80 infect equine tracheal 
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explants, as robust numbers of cells showed infection by expression of the viral antigen 
NP. Unfortunately, the E derm cells are unable to survive in infection conditions much 
beyond the 72 hour time point, even without infection, so it was not possible to extend the 
infection course to determine whether this was the case.  
 
In avian cell culture, Uruguay/63 had no significant replication advantage over the 
more recent EIV. The kinetics of replication were very similar with low peak titres and a 
very small percentage of cells expressing virus antigen. The avian control was able to enter 
up to 10% of cells, express NP and replicate to a significantly higher titre than the two 
EIVs. It seems that Uruguay/63 is not wholly “avian” in nature and that some level of 
mammalian-adaptation had already occurred prior to its isolation. This fits with the 
hypothesis that H3N8 EIV was introduced from birds in the 1950s and had been circulating 
in horses for nearly a decade prior to its identification and isolation115. Whether this virus 
reached a threshold value of clinical severity or outbreak size to be noticed is an interesting 
question.  
 
Polymerase-swapped reassortant viruses appear to show intermediate kinetics of 
replication to their two parental virus strains in infection of mammalian-derived cell 
monolayers. In MDCKs, the shape of the virus growth curve remained unchanged, with the 
peak titres intermediate between that of Uruguay/63 and Ohio/03. In E derm infection, the 
kinetics remained most similar to that of Uruguay/63, however the polymerase complex 
swaps attained higher titre than the Uruguay/63 parental virus. The Ohio/03 polymerase 
complex seems to be the predominant driver of the “adapted” phenotype of fast growth and 
high virus titres. Unfortunately, single segment reassortants could not be rescued to viable 
virus to identify which specific genes were responsible for this phenotype.  
 
The four other segments of Ohio/03 are also sufficient to give a replicative 
advantage to the Uruguay/63 polymerase over the Uruguay/63 wild type, suggesting that 
the story is more complicated. At least one of these segments is also important in the 
adaptation of Ohio/03 to equine infections. As Uruguay/63 was able to enter a high 
proportion of cells and induce expression of NP it seems unlikely that the viral entry 
protein HA is the major course of adaptation. Current studies suggest that the NS segment 
also plays an important role in EIV mammalian adaptation (Caroline Chauche, in 
preparation). 
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Additionally, in avian cell infections the polymerase complex of the more recent 
EIV is sufficient to put the virus at a greater replicative disadvantage than the Ohio/03 
parental virus. Adding the Uruguay/63 polymerase to the Ohio/03 backbone seemed to 
increase the titre somewhat at each time point. This seems to indicate that the Uruguay/63 
polymerase has more “avian-like” character than that of the Ohio/03 strain which has 
become more mammalian adapted. Overall, results obtained in this chapter suggest that 
EIV polymerase has become adapted to promote EIV replication in mammalian (equine) 
cells.   
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6 Results Chapter 3: In vitro studies on the replication 
efficiency of EIV polymerase complex  
 
6.1 Introduction  
 
The IAV virus polymerase is a key component of virus replication, providing both 
mRNA for protein synthesis and new genome copies to be packaged into progeny virions. 
The efficient activity of the polymerase complex is well known to be a crucial determinant 
of virus fitness in novel hosts 15,54,73,84,152,161,162. The first identified adaptive mutation of 
AIVs to mammalian hosts was the PB2 E627K mutation57,61,66. This mutation confers a 
“cold-adapted” phenotype and allows the polymerase to function in the cooler mammalian 
respiratory system (37 °C) instead of the avian enteric tract (41 °C). This mutation is 
highly conserved in mammalian-derived IAV strains. Despite circulating in horses for over 
50 years, the EIV classical lineage has retained the avian-signature glutamic acid at this 
position. The viral polymerase has to interact with host proteins for efficient replication74, 
so host compatibility is essential. Many other host specific restriction factors to polymerase 
have been characterised74,163, emphasising the requirement for effective mRNA and vRNA 
production in the virus.  
 
Given the different replicative capacities in mammalian cells of viruses containing 
polymerase of distinct EIVs demonstrated in the previous chapter, it was expected that 
these polymerase-distinct EIVs would exhibit different efficiency in avian or mammalian 
cells as EIV evolved. Minireplicon assays are commonly used as a measure of in vitro 
polymerase function 19,128,137. The minireplicon assay uses a reporter gene, such as 
luciferase, in a synthetic negative sense RNA “gene segment” with viral promoters. 
Luciferase expression acts as a reporter of polymerase activity and can be easily and 
accurately quantified. This allows examination of the polymerase activity as a correlate of 
fitness in each cell line, removing complicating factors such as cell entry and interferon 
evasion. These each make separate contributions to viral fitness, however their effect is 
difficult to determine independently as fitness components.  
 
 Due to the species-specific nature of the RNA pol I promoter, a separate reporter 
plasmid is required for each species.  The reporter for the human cell minireplicon system 
is well described 19 and reporters for swine137, chicken128 and canine138,139 cell minireplicon 
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systems also exist. In this chapter, the objective was to develop an equine-cell minireplicon 
system and to determine the extent of EIV polymerase adaptation to equine cells by 
comparing the polymerase activity (and therefore luciferase expression) in equine and 
avian cells. A highly “equine-adapted” virus seemed likely to have a more active 
polymerase complex in equine cells than a more “avian-like” one, although this might 
come at the cost of decreased polymerase activity in avian cells. The segment, or 
combination of segments, responsible for observed differences in polymerase activity 
could then be identified. The plasmid-based nature of this approach means it is amenable 
for site directed mutagenesis and mapping adaptive mutations. 
 
6.2 The equine Pol I promoter is present on chromosome 1 
 
Prior to the start of this project, the equine RNA pol I promoter had not been 
identified, although a sequence has since been published164. The equus caballus full 
genome was published in 2009165 (EquCab2.0), however it was not fully assembled with 
many scaffold and missing sections, especially in highly repetitive regions. The genome 
sequence also remains poorly annotated due to the limited research on horses. Genes are 
mostly described by homology to human or mouse counterparts and in very few cases have 
been verified in horses. In order to create an equine-specific minireplicon luciferase 
reporter, it was first necessary to locate the RNA pol I promoter sequence within the equus 
caballus genome. 
 
In nature, the RNA pol I is responsible for the transcription of ribosomal RNA 
subunits, as these also require exact ends with precisely define transcription initiation and 
termination. The coding sequences for ribosomal RNA subunits exist as cassettes of 
repeats on multiple chromosomes135,166–168 and within a 10 kbp region downstream of the 
RNA pol I promoter.  The 18S RNA segment had previously been annotated in several 
locations within the horse genome, so this was used as a starting point. The methodology 
described in Wang et al138 was used to examine regions upstream of ribosomal RNA 
cassettes for putative promoter sequences. Briefly, a BLAST search was performed within 
the NCBI database for regions with similarity to the published human RNA pol I 
promoter169.  
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Figure 6.1: Mapping the equine RNA pol I promoter. A) Schematic representation of the equine karyotype. 
The red circle represents the region in chromosome 1 shown in greater detail below. The 18S rDNA sequence is 
shown as a red box, the blue box represents the 500bp sequence with 60% homology to the human pol 1 promoter. 
B) The transcriptional start site (TSS) by alignment with other mammalian TSS previously described. T is highly 
conserved at +1 site (denoted by arrow). Conserved boxes within promoter region were also identified (not shown). 
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A 500bp region with 60% homology to the described human RNA pol I promoter 
was identified upstream of the 18S ribosomal subunit on chromosome 1 of the equus 
caballus genome (Figure 6.1 A). It was also confirmed to be similar (50% homology) to 
the canine promoter sequence published by Wang et al138. This region contained the 
elements conserved in most mammalian pol I promoters, repeated motifs that facilitate 
binding of the RNA pol I accessory proteins135. A putative transcriptional start site (TSS) 
was identified by alignment with previously described mammalian TSSs (Figure 6.1 B). 
This was important to prevent the addition of any extra nucleotides to the viral promoter in 
the minireplicon reporter as this would prevent the viral polymerase complex from binding 
and expressing the reporter gene.  
 
Despite repeated efforts, the identified putative promoter sequence was not 
amplifiable from genomic DNA by PCR. This was probably due to its high GC content and 
highly repetitive nature. The putative equine Pol I sequence was chemically synthesized 
and cloned into the reporter backbone. 
 
6.2.1 Mapped sequence is a functional RNA pol I promoter 
 
If the putative equine pol I promoter was indeed a bona fide promoter, it should 
facilitate the expression of the reporter cassette from the plasmid to negative sense RNA.  
In the presence of the viral polymerase complex, this can be transcribed to mRNA for 
luciferase translation. Expression of the reporter protein can be measured by light 
expressed when the luciferase substrate is added. 
 
To demonstrate this, the minireplicon reporter containing the putative equine 
polymerase promoter (eqPol 1) was transfected into 293T or E derm cells and compared to 
the minireplicon reporter containing the human pol I promoter (hPol1). The reporter only 
control (ROC) contained only the reporter plasmid and tested for “leaky” expression of the 
luciferase reporter gene without the presence of a viral polymerase. All other readings were 
normalised to the ROC to account for background reading. Each reporter was co-
transfected with individual plasmids containing the four polymerase segments (PB2, PB1, 
PA and NP) of Ohio/03 to test its ability to express luciferase in a viral polymerase 
dependant manner. Ohio/03 was chosen as it is the most “equine-adapted” EIV of those 
cloned into reverse genetic cassettes and would be predicted to have the highest 
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polymerase activity and therefore the strongest signal in this assay. Specificity of the 
reporter was tested by the omission of one of the four polymerase plasmids. This would 
measure the background luciferase expression in the absence of an active viral polymerase.  
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Figure 6.2: Equine minireplicon reporter is active in equine cells demonstrating promoter specificity. 
Luciferase activity in human (A) or equine (B) cells co-transfected with minireplicon reporters containing human 
(hPol1) or equine (EqPol1) pol 1 promoters were transfected alone (ROC) or with full (Oh+) or partial (Oh-) Oh03 
virus polymerase. Bars indicate mean value with SEM of three independent experiments. C) Confluent E derm 
monolayer were transfected with a constitutive GFP. Maximum transfection efficiency was determined by FACS 
and found to be 25% 
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In human cells, the human reporter alone (ROC) gave no luciferase expression 
above background. When transfected alongside only three of the Ohio/03 polymerase 
segments, no luciferase activity above that of the ROC was observed. Figure 6.2A shows 
the control lacking PB2, and removal of PB1, PA or NP had identical effects (not shown). 
However, when transfected into 293T cells alongside the complete Ohio/03 polymerase, 
the human reporter has an activity of one thousand-fold over background. This system has 
been in use for many years and it provided an excellent benchmark for the equine 
minireplicon system. 
 
 In the human 293T cells, the equine reporter alone (ROC) was comparable to 
background readings (Figure 6.2A). The incomplete polymerase controls also did not raise 
luciferase levels. With complete Ohio/03 polymerase, the equine minireplicon reporter 
gave a strong luciferase reading comparable to the human one. The identified equine pol I 
putative promoter was specifically activated by a viral polymerase complex, and these 
results show that it is indeed a bona fide pol I promoter. 
 
In the equine cells (Figure 6.2 B) the human reporter was not able to produce any 
luciferase activity above background readings. The ROC, 3 segment control and full 
polymerase trial all gave comparable luciferase results. The equine reporter, with the full 
virus polymerase, gave a 10-fold increase in luciferase activity over both the ROC and the 
three-segment control. This was a much weaker induction of luciferase activity than was 
seen from the same reporter in the human cells, despite the mismatch in promoter and 
accessory proteins in those cells. 
 
On investigation, the limiting factor was determined to be the transfection 
efficiency of the equine E derm cell line. 293Ts are highly transfectable epithelial-derived 
cells that when transfected with a constitutively expressing Green Fluorescent Protein 
(GFP) plasmid have a reliable transfection efficiency of over 90% as determined by FACS 
for GFP expression (data not shown). However, E derms are a dermal fibroblast cell line 
with poor transfection efficiency. Despite extensive optimisation, maximum transfection 
efficiency for the single GFP plasmid in E derms was 25% (Figure 6.2 C). The 
minireplicon assay depends on co-transfection of four protein-coding plasmids plus the 
reporter plasmid all into the same cell. At such low transfection efficiencies, the number of 
cells containing all 5 plasmids and successfully reconstituting the RNP plus reporter is 
likely to be very small. The Poisson distribution estimates successful minireplicon 
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reconstitution in 12 cells per assay, which explains the poor signal. Attempts to source or 
create an alternate equine cell line were unsuccessful.  
 
6.3 Late EIVs have stronger polymerase activity than early EIVs 
in mammalian cells but not in avian cells. 
 
In order to quantify the “adapted” phenotype of recent EIV polymerase Ohio/03 
noted in the previous chapter, the polymerase activity, as measured by minireplicon assay, 
in human (293T), equine (E derm) and avian (DF-1) cells of a panel of EIV polymerases 
was. These included the “avian-like” Uruguay/63, the “equine-adapted” Ohio/03, and the 
polymerase of an intermediate virus, Fontainebleau/79. The included the polymerase of 
Jilin/89 was included as a separate avian-like EIV. The laboratory-adapted strain A/Puerto 
Rico/8/1934 (PR8) was also included as a positive control as it has been shown to have 
strong activity in both human and avian cell lines 137,162. All values were normalised to the 
luciferase expression driven by the Ohio/03 polymerase in that cell line for ease of 
comparison. 
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Figure 6.3: Relative activity of evolutionarily distinct EIV polymerases is dependant on cell type. A) 
Minireplicon assay for polymerase activity in human (293T) cells for old (Uruguay/63), young (Ohio/03) and 
intermediate (Fontainebleau/79) EIVs. The mouse adapted strain (PR8) and un-passaged Jilin (Jilin/89) were 
included for purposes of comparison. The same viruses were assayed for polymerase activity in (B) equine (E 
derm) and (C) chicken (DF-1) cells. Bars indicate mean value with SEM of three independent experiments. 
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The polymerase complex of the laboratory-adapted PR8 and most recent EIV 
Ohio/03 exhibited the highest luciferase activity in 293T cells (Figure 6.3A). By contrast 
Uruguay/63, Fontainebleau/79 and Jilin/89 show reduced or no activity and were not 
significantly different to each other (P>0.05, one-way ANOVA). Western blot showed all 
proteins were expressed from relevant plasmids (data not shown). This result suggests that 
in human cells there appears to be a progressive increase in polymerase activity the later 
the virus was isolated in a manner consistent with polymerase adaptation to efficient action 
in mammalian cells. Jilin/89 is a separate introduction, but also seems to have an “early” 
EIV phenotype of inefficient polymerase activity in mammalian cells. 
 
In E derms (Figure 6.3B), the polymerase complex of Ohio/03 and PR8 were the 
only ones that displayed any detectable activity. The luciferase outputs of the remaining 
virus polymerases were below the threshold of detection of this system. This is probably 
due to the low sensitivity of the equine minireplicon system, where the highest signal 
obtained was only a one-log increase over background. In the much more sensitive 293T 
minireplicon, the Ohio/03 signal was three logs higher than background measurements. It 
was not possible to determine whether there was a progressive increase in polymerase 
activity from Uruguay/63 to Fontainebleau/79 to Ohio/03 in the equine cells. As both 
mammalian systems showed the same trend in high- vs. low-activity polymerases, to use 
the more sensitive human system was chosen as the mammalian model going forward. 
 
In DF-1 cells (Figure 6.3C), all the virus polymerase complexes tested produced 
comparable luciferase levels, with the exception of Jilin/89, which was significantly lower 
(P < 0.0001 one-way ANOVA). Increased polymerase activity in mammalian cells did not 
correlate with any reduction in activity in avian cells. Rather, the polymerase complex of 
Ohio/03 seems to be the most active in all cell types tested suggesting an overall 
improvement as opposed to a trade-off. 
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6.4 Reassortant polymerase complexes display PB1/PB2 subunit 
incompatibility  
 
The experiments described above showed that avian-like EIV polymerases display 
low activity in mammalian cells, whereas equine-adapted EIV polymerases were much 
fitter. The purpose was to determine whether observed differences were due to adaptive 
mutations in one or more of the components of the polymerase complex. In order to 
identify which genes were responsible for the increased polymerase activity in mammalian 
cell lines, minireplicon assays were performed in 293T cells using plasmids encoding the 
polymerase genes from either Uruguay/63 and Ohio/03 (Figure 6.4 A) or Fontainebleau/79 
and Ohio/03 (Figure 6.4 B) in reassortant polymerase complexes. Uruguay/63 and 
Fontainebleau/79 combination reassortants were also tested, but gave very low activity in 
all combinations and so are not shown.   
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Figure 6.4: EIV polymerase subunits PB1 and PB2 are not uniformly compatible in reassortment. A) 
Minireplicon assay for polymerase activity in 293T (human) cells with indicated genes from Ohio/03 (blue) and 
Uruguay/63 (green). B) Minireplicon assay for polymerase activity in 293T (human) cells with indicated genes from 
Ohio/03 (blue) and Fontainebleau/79 (yellow). Bars indicate mean value with SEM of three independent 
experiments. 
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In reassortants between Uruguay/63 and Ohio/03, several combinations gave no 
luciferase activity, even when the majority of the segments were from the high-activity, 
“equine-adapted” Ohio/03 virus (Figure 6.4 A). There was no activity in polymerases 
where the PB1 and PB2 subunits came from different viruses, suggesting an 
incompatibility between these segments. Viruses with PB1 and PB2 from one virus and PA 
and NP from the other had an intermediate phenotype between the two wild type viruses. 
Incidentally, this showed that all of the segments of the Uruguay/63 polymerase were 
functional in the 293T system as the PB1 and PB2 gave luciferase activity when paired 
with the Ohio/03 PA and NP, and vice versa. Although these reassortants were active at a 
low level (10% of Ohio/03), it is only the complete Uruguay/63 that is completely inactive.  
 
In reassortants between Fontainebleau/79 and Ohio/03, polymerases with the PA 
and NP segments of Ohio/03 showed high activity comparable to Ohio/03 wild type 
regardless of the origin of the PB1 and PB2 segments (Figure 6.4 B). Polymerase 
complexes with PA and NP from Fontainebleau/79 showed activity comparable to 
Fontainebleau/79 wild type. There was no effect of having PB1 and PB2 from different 
viruses similar to that observed in reassortants between Uruguay/63 and Ohio/03. 
Reassortant PB1 PB2 pairings were active, indicating the segments were fully compatible. 
These results indicate that PA and NP are the major drivers of the adapted polymerase 
phenotype for this combination of viruses. 
 
To investigate the incompatibility between the PB1 PB2 pairing of Uruguay/63 and 
Ohio/03, the amino acid sequences of the proteins were aligned. Sixteen amino acid 
differences were found in PB1 and 14 in PB2. The positions of the changed amino acids 
were mapped onto the published structure for the PB1/PB2/PA polymerase complex bound 
to the viral promoter 170 using the PyMol program171. Although it must be noted that this is 
a reconstruction of the polymerase of an H18 bat influenza strain, and not one closely 
related to the viruses of interest, it is the only published structure for the RNA bound 
polymerase complex. The aim was to identify changes in each protein which were spatially 
close to each other and when mismatched might be responsible for the loss of interaction 
compatibility. 
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Figure 6.5: Candidate amino acids to determine EIV PB1-PB2 compatibility. PB1 and PB2 sequences of 
Uruguay/1963 and Ohio/2003 were compared and differing amino acids were mapped onto a published IAV 
polymerase structure170. Yellow indicates PB2 amino acid chain, red indicates PB1 and green indicated the PA 
protein. Changed amino acids on each protein in close proximity were considered candidates for determining 
compatibility. Two pairs of candidate amino acids were identified.  
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 Page 111 
 
 
Two pairs of changes at the PB1/PB2 interface were identified and are highlighted 
on Figure 6.5. The pairings were PB1 Q621K with PB2 V109I and PB1 E738D with PB2 
S12L (the first amino acid is the one found in Uruguay/63 and the second is its equivalent 
residue in Ohio/03). PB1 E738D-PB2 S12L was considered a poorer candidate pairing for 
two reasons. Firstly, the two residues were less closely placed on the model structure, 
making a direct interaction less likely. Secondly, the Fontainebleau/79 polymerase was 
found to have PB1 738E and PB2 12S residues similarly to Uruguay/63. This would not 
explain the compatibility between the PB1 and PB2 subunits of Fontainebleau/79 and 
Ohio/03. Consequently the PB1 Q621K PB2 V109I pairing was selected as the most likely 
candidate for the compatibility determinant.  
 
6.4.1  Amino acid 621 of PB1 is key for PB1-PB2 compatibility between 
segments of evolutionarily distinct EIVs 
 
To determine the effect of restoring the PB1 Q621K PB2 V109I pairing in PB1 and 
PB2 segments of different origins, plasmids with swapped pairings were constructed. 
Using site-directed mutagenesis, plasmids with Uruguay/63 PB1 621K and PB2 109I were 
created, as well as Ohio/03 PB1 621Q and PB2 109V. These were used in mini replicon 
assays in 293T cells with reassortant polymerases as described above. The hypothesis was 
that restoring the natural pairing at these sites would rescue interaction between PB1 and 
PB2 from different sources and therefore rescue polymerase activity. 
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Figure 6.6: Restoring amino acid pairing at PB1 Q621K and PB2 V109I rescues polymerase activity in 
Uruguay/1963 but not Ohio/2003 based polymerases. A) Minireplicon assay for polymerase activity in 293T (human) 
cells with indicated genes from Ohio/2003 (blue) or single amino acid mutants Ohio PB1 621Q and Ohio PB2 109I 
(dark blue) and Uruguay/1963 (green). B) Minireplicon assay for polymerase activity in 293T (human) cells with 
indicated genes from Ohio/2003 (blue) and and Uruguay/1963 (green) or single amino acid mutants Uruguay PB1 
621K and Uruguay PB2 109V (dark green). Bars indicate mean value with SEM of three independent experiments.  
  
 Page 113 
 
 
Introducing PB1 621K or PB2 109I into the relevant Ohio/03 segments singly or 
together did not affect the activity of the Ohio/03 polymerase in minireplicon activity 
(Figure 6.6A). This appears to suggest that disrupting this putative interaction site is not 
sufficient to prevent efficient interaction between these two subunits. In contrast, Ohio/03 
PB2 109V was able to rescue some low level activity when the PB1 segment was from 
Uruguay/63 and PA and NP were from Ohio/03. This was not the case when the PA and 
NP were from Uruguay/63.  
 
Changes to the Uruguay/63 segments (Figure 6.6B), PB1 621E or PB2 109V, made 
no difference to its lack of luciferase activity, either singly or together in the context of the 
whole Uruguay/63 polymerase. However, when Ohio/03 PB1 was added, the Uruguay/63 
PB2 109V was able to restore a small but significant (p=0.03) amount of activity. With the 
Ohio/03 PB2, Uruguay/63 PB1 627K restored activity to 10% of the Ohio/03 wild type. 
This restoration of minireplicon activity was even more dramatic when PA and NP were 
from the Ohio/03 virus, restoring levels comparable to wild type Ohio/03 with high 
significance (p<0.001). Interaction between Ohio/03 PB2 and Uruguay/63 PB1 or 
Uruguay/63 PB2 and Ohio/03 PB1 was restored. This suggests that the PB1 Q621K PB2 
V109I pairing was at least partially responsible for PB1 PB2 protein interactions. Although 
it is not the whole story as Ohio segments retain interaction despite putative pairing 
disruption. 
 
Overall, our results show that introduction of either PB1 or PB2 from avian-like 
EIVs into the polymerase complex of equine-adapted EIVs abolishes polymerase activity. 
However, single mutations in the avian-like polymerase segments (621 in PB1, 109 in 
PB2) restore the functionality of the polymerase complex, suggesting that they are critical 
for protein-protein interactions. 
 
6.5 PA and NP are the major drivers of increased polymerase 
activity in EIVs 
 
The PB1 PB2 segment incompatibility is insufficient to explain the greatest part of 
the difference in polymerase activity between the EIV wild type viruses in human 
minireplicon assays. In order to further understand which of the PA and NP genes were 
driving increased polymerase activity in mammalian cell lines, minireplicon assays were 
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performed with reassortant complexes comprising segments from either Uruguay/63 and 
Ohio/03 (Figure 6.7 A) or Fontainebleau/79 and Ohio/03 (Figure 6.7 B). Uruguay/63 and 
Fontainebleau/79 combination reassortants were also tested, but gave very low activity in 
all combinations and therefore are not shown. 
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Figure 6.7: EIV polymerase subunits PA and NP contribute to increased polymerase activity. A) 
Minireplicon assay for polymerase activity in 293T (human) cells with indicated genes from Ohio/2003 (blue) and 
Uruguay/1963 (green). A) Minireplicon assay for polymerase activity in 293T (human) cells with indicated genes 
from Ohio/2003 (blue) and Fontainbleau/1979 (yellow). Bars indicate mean value with SEM of three independent 
experiments. 
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In reassortants between Uruguay/63 and Ohio/03, replacing either PA or NP of the 
Ohio/03 complex with the Uruguay/63 segment reduced activity ten-fold (p<0.001) and 
replacing both gave a slight but significant further reduction (p<0.05). The effects of PA 
and NP genes were separate, but of comparable strengths. Conversely, the addition of 
either PA or NP from Oh03 into the U63 polymerase complex increased the polymerase 
activity over ten-fold. This effect appeared to be additive, as adding both the Ohio/03 PA 
and NP increased the activity of the Uruguay/63 polymerase approximately one hundred 
fold.  
 
A similar pattern was seen in reassortants between Fontainebleau/79 and Ohio/03. 
Substituting the Fontainebleau/79 PA or NP into the Ohio/03 polymerase reduced the 
luciferase activity by 1 log. Both of these with the Ohio/03 PB1 and PB2 reduced 
luciferase level below that shown by the Fontainebleau/79 wild type polymerase. With the 
Fontainebleau/79 PB1 and PB2, adding either the PA or NP of Ohio/03 increased 
luciferase activity 10 fold over wild type. The effect of the two segments was again 
separate but comparable. Adding both Ohio/03 PA and NP to the Fontainebleau/79 PB1 
and PB2 allowed full rescue of polymerase activity to a similar level to Ohio/03 wild type.  
 
Overall these results suggest that the increase in polymerase activity of the Ohio/03 
polymerase compared to the polymerases of earlier EIVs Uruguay/63 and 
Fontainebleau/79 were due to the PA and NP segments. Each makes a separate and 
independent contribution to the increased adaptation of the Ohio/03 polymerase to 
increased activity in mammalian cells. Further work will be required to determine which 
adaptive mutations contribute to increased polymerase efficiency and what specific 
molecular determinants are responsible for this effect.  
 
6.6 Discussion: 
 
The aim was to develop a minireplicon reporter assay in equine cells in order to 
investigate the polymerase activity of evolutionarily distinct EIVs and to identify the 
genomic segment/s that contributed to its adaptation to horses. The equine Pol I promoter 
was mapped to a region on chromosome 1, 6kbp upstream of the 18S ribosomal gene. This 
region was successfully synthesized and cloned into the negative sense luciferase construct 
for minireplicon assays. The region identified was identical to that published separately by 
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Lu et al164. The specific activity of the putative promoter sequence was demonstrated, 
which confirmed it was an active pol I promoter in equine cells. 
 
However, the E derm cells were not suitable for transfection-based assays such as 
mini replicons due to their low transfection efficiency. This caused the equine minireplicon 
set up to have very poor sensitivity and a low signal-to-noise ratio. Initial tests determined 
that the pattern shown in equine minireplicon assay is very similar in human mini replicon, 
that is the viruses with detectable activity in the equine system (Ohio/03 and PR8) have 
very high activity in human cells. Viruses with low activity in the human mini replicon did 
not have detectable activity in the equine minireplicon system. For this reason, it was 
decided to use the well-established human minireplicon system as an experimental 
platform to examine mammalian adaptation of the EIV polymerase.  
 
In this mammalian system, the polymerase complex of evolutionary distinct EIVs 
displayed a time-dependent efficiency in terms of polymerase activity. The earliest, and 
most “avian-like” EIV, Uruguay/63, was unable to produce any luciferase activity above 
background levels, whereas the “equine- adapted” Ohio/03 had comparable polymerase 
activity to the laboratory-adapted PR8. This appears to be strong evidence for the 
adaptation of the polymerase complex to the novel mammalian host and supports what had 
previously been observed in reassortant viruses carrying the two polymerases. The Ohio/03 
polymerase is significantly “fitter” in mammalian cells than the Uruguay/03 polymerase. 
This is also comparable to the work of Lu et al164, who found that a recent Heilongjiang/13 
EIV isolate had a polymerase activity 10 fold higher than the more distant Miami/63 when 
tested in their system. 
 
 The reduced polymerase activity, and “fitness”, of Jilin/89 in chicken cells is 
unexpected, as it had been assumed to be closely avian related. However, it has been 
shown in 1990 that the passaged virus was no longer able to infect ducks115, its presumed 
host species, which may be related to its replication deficit here in vitro. The exact 
mechanism of this loss in fitness is not clear, and may not be possible to elucidate without 
rescue of infectious virus. The loss of the ability to infect the original host species after 
becoming established in the novel host is not unique however. The H3N8 CIV, which was 
derived from circulating EIV, no longer efficiently infects horses121. This suggests that 
increased fitness in one host may come at the cost of decreased fitness in the original host.  
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However, increased polymerase activity in mammalian cell minireplicon assay was 
not correlated with a decrease in polymerase activity in avian cell minireplicon assay. 
Ohio/03 exhibited the highest polymerase activity in avian cell culture, as well as strong 
activity in mammalian cells. A trade off had been expected, with the polymerase adapting 
to high activity in mammalian cells but losing efficiency in avian cells. No loss of 
efficiency in recruiting avian-host factors occurred, instead the Ohio/03 polymerase has 
become optimised. A similar phenomenon has been observed previously by Moncorge et 
al137, looking at the pH1N1 derived from swine (A/human/England/195/2009) and its 
ancestral virus A/Duck/Bavaria/77. The pandemic virus polymerase was able to drive 
luciferase activity in minireplicon assays in human and swine cells unlike the avian virus, 
but was also significantly more active in the avian cell minireplicon system than the 
ancestral avian virus polymerase. 
 
The minireplicon result is contrary to what was observed in avian cell infection in 
the previous chapter, where reverse genetic viruses containing the Ohio/03 polymerase 
were at a replicative disadvantage compared to those with the Uruguay/63 polymerase 
(Figure 5.5). This indicates that the level of polymerase activity as measured by the 
minireplicon assay should be considered with caution, as other factors are clearly involved 
in the overarching phenotype of “adaptation” and may not translate directly into increased 
fitness. 
 
Using reassortant polymerase complexes to investigate which genes are responsible 
for phenotypic differences in mammalian cells, subunit incompatibility was discovered 
between the Uruguay/63 and Ohio/03 PB1 and PB2. This was shown to be partially due to 
the disruption of a pair of residues at the PB1-PB2 interaction face. Disrupting the crucial 
interactions between virus proteins is currently a very exciting area of research with the 
potential to uncover novel anti-viral drugs70 so this may be worth further investigation. It is 
also of note that pandemic viruses generated by reassortment maintain such pairings of 
segments within their polymerase genes. PB2 and NP have been shown to be closely 
associated in this manner172. Knowledge of these constraints may be of use when 
attempting to predict the emergence of new pandemic strains. 
 
In the minireplicon system, PA and NP appear to be the major drivers of the 
“adapted” phenotype. PA has been shown to have particularly high rate of non-
synonymous mutation in the evolution of the EIV lineage (16 amino acid changes)119,173, 
which would be consistent with evolutionary pressure to become “equine-adapted”. The 
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requirement for efficient polymerase activity may explain this pressure. However, the 
number of amino acid changes will make it more difficult to identify those that are 
required for the “adapted” phenotype and those that are merely incidental, although one 
cluster of amino acid changes around position 340 presents an intriguing implication of 
strong selective pressure in this region. The mechanism of NP action also remains to be 
elucidated, however it is possible that it is related to escape from mammalian host 
restriction factor MxA. MxA interaction with NP has been shown to form large complexes 
and inhibit the transcription of a mini-genome luciferase marker32. Lu et al demonstrated 
that a recent EIV complex was much more resistant to this inhibition than an older virus. 
Several differences in the NP sequences of Uruguay/63 and Ohio/03 were noted in regions 
previously described as relating to escape from the MxA so this appears to be an avenue 
worth pursuing. 
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7 General Discussion: 
 
This thesis aimed to find evidence of adaptation of EIV strains to the efficient 
infection of the horse host over the course of 50 years of circulation. It was expected that 
isolates from closer to the jump from birds in the early 1960s would be less fit in mammals 
than more recently isolated EIVs and that this difference in phenotype could be pinned to 
specific adaptive mutations in one or more segments of the EIV genome. To test this 
hypothesis the fitness of phylogenetically extinct viruses in the mammalian host were 
examined by three distinct methods; the phenotype of infection of ex vivo tracheal 
explants; the kinetics of replication in cell lines of different species origin; and the in vitro 
polymerase activity in cell of both mammalian and avian origin.  
 
Although this body of work is not exhaustive, some of the questions posed by this 
hypothesis can be answered here. There is evidence of change in the characteristics of the 
virus in every system tested. The early EIV Uruguay/63 displayed a distinct phenotype of 
infection of the equine tracheal explant to the more recent Ohio/03, whose phenotype was 
much more similar to that previously described for well-adapted viruses in other systems 
with bi-phasic replication kinetics. This was not accompanied by any increase in tissue 
damage, which supports the idea that a well-adapted virus will be less destructive in order 
to prolong the opportunity for replication of the maximum amount of virus before the host 
dies. This may also increase host-to-to transmission by extending the window for 
transmission.  
 
 In vitro, Ohio/03 was able to replicate more rapidly and to higher titres in 
mammalian cells than Uruguay/63. When the polymerase complex of Ohio/03 was 
substituted into Uruguay/63, the kinetics were those of Ohio/03. The polymerase of 
Ohio/03 was shown to have a far higher activity in mammalian cells than that of 
Uruguay/63 by minireplicon assay, and this phenotype was driven by the PA and NP 
subunits. No specific adaptive mutations have yet been identified in these gene segments, 
although it seems likely that they exist. Further work will be required to determine which 
of the identified amino acid differences are responsible for the changes in phenotype. 
 
The role of the IAV polymerase complex in the adaptation to a novel host species is 
well known 15,73,84, however much previous work has focused on the PB2 gene segment. 
The classical EIV lineage does not possess the PB2 627K mutation shared by the majority 
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of mammalian IAV strains 57,66 instead retaining the avian signature glutamic acid at this 
position. Nor has it acquired the trio of compensatory mutations described in the 2009 
pandemic H1N1 virus58. The mechanism of the polymerase adaptation was poorly 
understood up to now. This work highlights the role of the PA segment in host adaptation. 
Murcia et al have previously noted the high rate of non-synonymous mutation in the PA 
gene of the EIV lineage119. It seems likely that some of these changes are of adaptive 
benefit to the virus polymerase efficiency, although the specifics have yet to be 
determined. Of the 16 amino acids which differ between the PA protein of Uruguay/63 and 
Ohio, one or more may confer a specific advantage to the virus by increasing the efficiency 
of the polymerase in equine cells. This may be due to recruitment of host factors, or 
another mechanism. A four of changed amino acids are observed in a region of the gene 
which is also used in the expression of the frame-shifted protein PA-X, so these mutations 
may also affect the endonuclease role of this protein. The enrichment of changed amino 
acids around position 340 indicates a strong selective pressure on this region of the protein, 
although no interaction partners have been identified. 
 
The role of NP in host adaptation is less mysterious, as it has been associated in 
several host-specific roles including importin-α binding76 and escape from MxA 
restriction32,85. The NP of EIV has acquired known adaptive mutations which act by these 
mechanisms including G16D and N319K84. The NP of Ohio/03 also has several mutations 
in regions identified by Manz et al (2013) as being associated with MxA binding, although 
not the specific changes seen there. These seem likely candidates for increased efficiency 
of the polymerase as MxA restriction has been shown to reduce polymerase activity in 
minireplicon assays by complexing with the viral proteins and titrating them out of the 
available pool32. Escaping or reducing the binding of MxA should negate this block. 
 
It was interesting to note that the increase in polymerase activity observed in 
mammalian cells was not correlated with a decrease in efficiency in avian cells. Adaptive 
mutations canonically come at a fitness cost in the original host174. Previous studies 
suggest that adaptation to co-opt the mammalian ANP32A75 is the major driver of avian to 
mammalian polymerase adaptation, stimulating the E627K switch. Altering the polymerase 
to accommodate the mammalian factor would result in loss of interaction with the longer 
avian version. However, this did not occur. The Ohio/03 polymerase showed the highest 
level of polymerase activity in avian minireplicon assays, above that of PR8 which has 
previously been shown to have high activity162.  The polymerase complex of Ohio/03 
seems to be more efficient in a general sense than that of Uruguay/63. This raises the 
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question of why Uruguay/63 has such a poor polymerase, despite its ability to infect a 
novel host species efficiently enough to give rise to a new IAV lineage. This may reflect 
the choice of avian cell for minireplicon assay, as there is no evidence that the AIV 
progenitor of the EIV lineage was a chicken virus. It seems likely that, just as barriers exist 
for the infection of different mammalian species, not all avian species are interchangeable 
as hosts for influenza virus infection. This may prove an interesting avenue for further 
consideration, not taken into much account in previous studies.  
 
The scope of this study was limited to the action of the polymerase, which omits 
many crucial factors of viral adaptation to the novel host. The action of the innate immune 
system to induce an antiviral state is dependant on host specific factors such as MxA. 
These exhibit variation between the various host species of IAV, and therefore the viral 
proteins must adapt to control them. The best characterised of the IAV interferon 
antagonists is NS1 which acts by a multitude of mechanisms to evade innate and intrinsic 
immunity. Adapative changes in NS1, including a substation terminal truncation have been 
observed during the course of EIV circulation in horses (Chauche, in preparation). The 
influence of adaptive immunity on the antigenic proteins HA and NA are also not 
considered here. Although transmission between host individuals is the defining feature of 
a novel lineage, it is very difficult to correlate increased replication in vitro, or even ex 
vivo, with increased transmission between hosts. Many factors crucial to host transmission, 
such as environmental stability of virions and the influence of environmental conditions175, 
cannot be recapitulated within this experimental system. Although horse transmission 
studies have been conducted in the past173 they have not been comparative between 
isolates.  
 
The major conclusion of this thesis is that a recent EIV isolate does show evidence 
of a more “mammalian adapted” phenotype than earlier EIV isolates from closer to the 
avian-mammalian jump event. In particular, the action of the polymerase in producing viral 
proteins in mammalian cells is more efficient in the recent isolate, and this is due to the 
action of the PA and NP subunits. In contrast to previous studies of other IAV lineages, the 
role of PB2 in the adaptation of the EIV polymerase is minor.  
 
Further work is required to map and characterise the specific adaptive mutations in 
PA and NP. Several candidate mutations have been identified in NP at sites previously 
implicated in mammalian adaptation, which seem promising lines of inquiry. The mini 
replicon system is suitable for the exploration of MxA resistance by the effect of co-
 Page 123 
 
transfecting an MxA-expressing plasmid on luciferase expression78, and the plasmid-based 
nature of the assay lends itself to the examination of specific mutations.  In the case of PA, 
fewer adaptive mutations have previously been characterised.  One study has suggested a 
disruption in the formation of the hetero-trimeric complex67,176, which was visible by co-
immunoprecipitation of the complex components. There may be additional uncharacterised 
mechanisms of adaptation remaining to be resolved. 
 
One finding of this work, which initially seemed incidental, may in fact have much 
wider implications. This is the acquired incompatibility between polymerase segments 
between two very closely related viruses. The interactions between the subunits of the 
polymerase are clearly vital to its efficient function, however they appear to be easily 
disrupted by as few as seven amino acid changes. The question raised is how reassortant 
viruses, which are observed not in-frequently in nature, manage to overcome this barrier. 
Pandemic viruses such as pH1N1 have often polymerase segments from two or more 
origins177. Understanding of the requirements for compatibility may help to predict 
potential reassortant events in the future. Increased knowledge of the subunit interface may 
also be used to develop antiviral drugs, as this would be an excellent virus-specific target. 
 
Influenza A viruses pose a threat to human and livestock health due to their ability 
to emerge from the avian reservoir and establish new lineages in naïve host species. The 
WHO currently relies on surveillance of AIV isolates circulating in wild bird to identify 
high-risk strains and predict future threats in time to take containing actions101 such as 
poultry culls and vaccine production. Threat level is assessed by the presence of known 
mammalian-adaptive mutations accumulated by AIVs101. This study highlights gaps in the 
current understanding of these adaptive mutations, as the EIV linage contains of the known 
mammalian markers despite efficient mammalian infection. At the moment, EIV is an 
economic burden to the horse racing industry and poses little risk to human health178. 
However, given the rate of adaptation of this virus, and the recent establishment of the CIV 
lineage, it is not impossible that EIV could become a cause for concern.  
 
7.1.1 Further Work 
 
Further investigation of the subunit incompatibility phenomenon may be of value. 
It may be possible to map specific sites which are responsible for incompatibility using the 
minireplicon system as well as reverse genetics rescues. Immuno-precipitation assays may 
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reveal whether the interaction of subunits is abrogated or merely disrupted to the point of 
loss of function. It would be interesting to map these differences to a more relevant crystal 
structure, on a segment-by-segment basis if necessary. Since the noted differences lie 
outside of published segment interaction sites, full characterisation of the altered binding 
sites may increase understanding of the complex three-dimensional way in which the viral 
proteins interact with each other and host proteins. 
 
To fully elucidate the mechanisms of the adaptation of PA to increase polymerase 
activity in minireplicon assay, it would be necessary to generate chimeric and site-directed 
mutants to investigate the roles of region and specific amino acids singly and together. 
These would be used in minireplicon assays for polymerase activity and in protein shut-off 
assays to investigate potential effects of PA-X differences. An antibody pull-down assay 
for the region of interest, enriched for amino acid differences, may help to identify 
potential binding partners. This may shed light on the selective pressures that influence the 
evolution and adaptation of this segment in horses.  
 
A similar approach may be applicable to the investigation of NP. To confirm a loss 
of MxA binding, a pull down immuno-precipitation assay may be performed for NP to 
determine whether more MxA is associated with the NP of Uruguay/63 than that of 
Ohio/03. Alternatively, or additionally, MxA may be pulled down to determine the extent 
of interaction with NP of different origins. This may reduce any difficulties such as un-
equal antibody binding to the two proteins that may bias the results. As the equine MxA 
proteins have been mapped to chromosome 26 and their sequences are known179,180, 
exogenous equine MxA could be transfected in parallel with the minireplicon. A reduced 
attenuating effect for Ohio/03 compared to Uruguay/63 would provide support for the 
hypothesis.  
 
Following the identification of specific adaptive mutations at the in vitro level, it 
would be possible to introduce these into viruses using the reverse genetic plasmid sets 
generated in chapter 5. The effects of the adaptive mutations on viral replication could then 
be ascertained both in cell culture, and ideally in the ex vivo system. This will be of 
significant interest in determining the effects of specific adaptive mutations of EIV to 
equine infection in a physiologically relevant system.  
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